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INTRODUCTION  
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
  
 Airway management is of prime importance with regards to patient 
safety and is also the most important responsibility of anaesthesiologist to 
maintain a clear patent airway to facilitate administration and maintenance of 
anaesthetic agents besides sustaining the oxygen delivery through lungs. 
Hence various devices and methods were tried and used both by ancient and 
modern physicians for maintaining the airway and the ever-lasting search for 
the quick, safe and convenient method goes on. (1)  
 The cornerstone in the field of anaesthesia is the discovery of 
endotracheal intubation (2) and is usually done by direct laryngoscopy under 
direct vision. In the late 80s, only face mask and endotracheal tube (ETT) 
were the only means available to maintain the airway patency (3). Though 
endotracheal intubation is safe in healthy patients, it may trigger 
hemodynamic changes and induce reflex cardio-vascular responses such as 
hypertension, tachycardia and arrhythmias which may in-turn lead to life-
threatening complications like myocardial ischemia, left ventricular failure 
and cerebral haemorrhage (4, 5). 
To avert these reflex hemodynamic changes, alternate devices such as 
fibre-optic scope, light wand and laryngeal mask airway (LMA) were used (6).  
The laryngeal mask airway (LMA) designed by Dr. Archie Brain fills 
the niche between endotracheal tube (ETT) and the face mask (7). Since then 
 
 
 
many variants of LMA were introduced. The laryngeal mask airway (LMA) 
is a potential tool in the management of difficult airway and today it is widely 
used as a part of routine airway management in an elective setting (8,9). The 
hemodynamic response to the insertion of laryngeal mask Airway (LMA) is 
considerably less than that is observed after laryngoscopy and endotracheal 
intubation (10). 
The smooth insertion of laryngeal mask airway (LMA) entails 
adequate mouth opening with suppressed Airway reflex (11).  Various 
intravenous agents like thiopentone, etomidate, propofol and midazolam have 
been used for induction of anaesthesia with the purpose of attaining 
hemodynamic stability, attenuation of stress responses and maintenance of 
balance between myocardial oxygen supply and demand (12). 
 The most frequent anaesthetic agent used for insertion of laryngeal 
mask Airway (LMA) is propofol which is widely used in outpatient surgeries 
mainly because of the low incidence of postoperative nausea and vomiting 
besides providing satisfactory and smooth anaesthesia with quick recovery 
and amnesia (13). The recommended dose of propofol is 1- 2.5 mg/kg which 
provides the necessary jaw relaxation and the prohibition of reflexes like 
coughing or bucking following LMA insertion.  However, propofol is also 
associated with side effects like hypotension, bradycardia, prolonged apnoea 
and pain on injection (14). 
 
 
 
Etomidate is an IV anaesthetic agent which is used either alone or in 
combination with other agents for induction of anaesthesia and also for 
maintenance of anaesthesia in different contexts. It is a rapid onset short 
acting agent and it produces significantly less cardiovascular depression than 
the other induction agents. Etomidate does not depress the airway reflex and 
is also not associated with histamine release. Administration of etomidate 
may cause nausea, vomiting, pain on injection, myoclonus and adrenocortical 
suppression (15). 
When propofol alone is administered for insertion of laryngeal mask 
airway (LMA) it can be associated with complications like coughing, gag 
reflex and laryngospasm. To avoid these complications, numerous agents 
were tried along with propofol and also to decrease the hemodynamic 
instability.  
The combination of propofol and etomidate decreases the dose 
requirement for both the drugs, provides advantages of both the drugs such as 
better airway quality and muscle relaxation for LMA insertion and also has 
fewer effects on respiration and circulation as it provides hemodynamic 
stability and is much safer and more effective than propofol or etomidate 
alone. (13, 16, 17).  Etomidate has shown that it is superior in comparison to other 
drugs like remifentanil for combination therapy with propofol for insertion of 
laryngeal mask airway. Also Etomidate has provided a better hemodynamic 
stability in combination with propofol rather than combination of other drugs 
 
 
 
with propofol. (18). Studies have shown that reduction in sympathetic tone and 
direct venodilator effect of propofol is dose-dependent and in turn affects the 
hypotension produced by propofol which offsets the pressor responses of 
LMA insertion (19, 20, 21). 
With this backdrop, this study was carried out to assess efficacy and 
hemodynamic profile of the drug combinations with varying doses of 
propofol (0.5 mg/kg, 1.0 mg/kg, 1.5 mg/kg) and fixed dose of etomidate (0.2 
mg/kg) for smooth induction in aiding the insertion of laryngeal mask airway 
(LMA) among subjects posted for elective surgeries with ASA risk I or II.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBJECTIVES 
 
 
 
 
 
 
 
 
 
 
 
OBJECTIVES 
1) To compare the Haemodynamic parameters during LMA Insertion with same 
dose of Etomidate and varying doses of Propofol.  
2) To compare the ease of LMA insertion by number of attempts, total duration 
and efficiency of established airway. 
3) To compare the duration of apnea.  
4) To find out the incidence of side effects associated with the drugs and 
complications associated with LMA Insertion. 
 
 
 
 
 
 
                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
Airway management and Patient Safety is the most important aspect 
of management during general anaesthesia. Various devices that tried by 
ancient and modern physicians for maintenance of airway and delivery of 
anaesthetic agents.  The most important milestone in the field of anaesthesia 
was the discovery of endotracheal intubation and it is usually done by using 
direct laryngoscopy under direct vision (22, 23). The endotracheal intubation is 
the gold standard in safe and healthy patients. It has disadvantages of 
triggering hemodynamic changes and reflexes which can be dangerous to 
some groups of patients with other comorbidities (24, 25, 26, and 27).  
Endotracheal intubation is known to induce reflex cardiovascular 
responses such as hypertension, tachycardia, arrhythmias, myocardial 
ischemia, infarction besides hypoxia, hypercapnia, laryngospasm, 
bronchospasm and sometimes rarely increased intracranial pressure and 
increased intraocular pressure (28, 29, and 30). 
To avoid this reflex hemodynamic changes, alternate devices in the 
form of Supraglottic Airway devices (SADs) which includes laryngeal mask 
Airway (LMA) and its variants are used (31, 32, 33). The first of the modern 
supraglottic Airway device was the classic laryngeal mask Airway (cLMA) 
which rapidly became the standard alternative to tracheal intubation 
Dominion status initially restricted the alarm for anaesthesia in the minor 
extremities surgery with spontaneous breathing, Dr. Archie Brain used the 
 
 
 
classic LMA for gynaecological laparoscopic surgeries with controlled 
ventilation(34, 35, 36).  
These supraglottic devices which have their own advantages and 
disadvantages when compared to traditional and conventional face mask and 
endotracheal tube intubation (37, 38) as mentioned below:  
Indications for the use of supraglottic airway devices 
1. For elective ventilation:  the supraglottic Airway devices are an effective 
alternative for mask anaesthesia in the operating theatres and also an 
alternative for the endotracheal tube intubation for short and elective surgical 
procedures under general anaesthesia (37).  Sometimes to avoid the damage to 
vocal cords and to avoid the complications of endotracheal intubation such as 
in professional singers Supraglottic Airway devices are preferred. 
2.  In difficult Airway:  supraglottic device is an integral component of both 
anticipated and unanticipated difficult Airway management.  They are used 
as a rescue device in situations of failed intubation or ventilation.  LMA 
insertion can be tried while preparing for cricothyroidotomy in a patient who 
cannot be intubated or ventilated (38). 
3. For cardiac arrest:  According to the American heart Association 
guidelines for cardiopulmonary resuscitation LMA for airway management is 
an alternative for intubation during cardiac arrest 
 
 
 
4.  As a conduit for intubation:  supraglottic airway devices can be used for 
this purpose when intubation is unsuccessful.  The endotracheal tube can be 
passed through the supraglottic airway device or using a special intubating 
LMA either directly or by assistance with the bougie or a fibre optic scope 
5. Can also be used as a bridge to extubation  
Advantages of supraglottic airway device 
1. Hands-free maintenance of the airway which removes the fatigue 
component to the operator (39). 
2. These are more secure and reliable means of maintenance of airway 
3. Also there are lesser chances of gastric insufflations 
4. Lesser hemodynamic response and reflex than intubation. 
 Disadvantages of supraglottic airway devices 
The incidence of sore throat is higher   roughly about 17% for supraglottic 
airway devices as against 3 % for facemasks. 
Contraindications for supraglottic airway devices (40, 41, 42, 43, 44)  
1. Obstruction in the upper Airway in the form of tumour, abscess, 
hematoma, edema etc... 
2. Restricted mouth opening in the form of trismus 
 
 
 
3. All patients at risk of aspiration such as no adequate fasting, intestinal 
obstruction and patients undergoing emergency surgeries. 
4. In patients with disrupted upper Airway, facial trauma, burns following 
caustic ingestion 
5. Among morbidly obese patients, pregnancy more than 14 weeks, patients 
who have received prior opioids medication 
6. Conditions compromising lung compliance or increased resistance to 
breathing such as pulmonary Fibrosis, status asthmaticus etc.   
However newer and safer supraglottic Airway devices provide high sealing 
pressures so that they can be used in conditions like obesity and stiff lungs (45, 
46) 
Miller’s Classification of supraglottic Airway devices (47) 
A. Cuffed Peri-laryngeal sealers 
1. Without directional sealing: Laryngeal Mask Airway (LMA), Intubating 
Laryngeal Mask Airway (ILMA), Soft-seal LM, Ambu LM 
2. With directional sealing: Proseal- Laryngeal Mask Airway (PLMA) 
B. Cuffed Pharyngeal sealers 
1. Without esophageal sealing cuff: Cobra-PLA 
 2. With esophageal sealing cuff: Laryngeal tube (LT), Laryngeal tube 
suction (LTS), Combitube 
 
 
 
C. Cuffless Pre-shaped sealers: Stream-lined liner of the pharynx airway 
(SLIPA), I-gel, Baska Mask. 
 
Laryngeal Mask Airway (LMA) 
The laryngeal Mask Airway was conceived and designed by Dr. 
Archie Brain in 1981 and after years of research it was finally released for 
use in 1988 (48). The laryngeal Mask Airway clearly fills a niche between the 
face mask and the endotracheal tube in terms of both Anatomical position 
and the degree of invasiveness. It is also reusable as set is made from Medical 
grade silicone rubber. 
LMA contains three main components such as airway tube, an 
inflatable mask and the mask inflation line. 
 
 
 
Figure showing Classic LMA 
Table showing Laryngeal Mask Airway (LMA) size and cuff 
inflation volume 
Weight in 
Kg 
LMA size 
Cuff 
inflation 
volume 
<5 1 4 
5-10 1.5 7 
10-20 2 10 
20 – 30 2.5 14 
30 – 50 3 20 
50 – 70 4 30 
70 – 100 5 40 
>100 6 50 
Figure showing LMA in various sizes 
 
 
 
The following is the standard method of insertion of laryngeal mask Airway 
(LMA) (49): 
  1. First of all anaesthesia should be deep enough to permit Insertion of LMA 
and we should not try to insert the LMA immediately following barbiturate 
induction unless a relaxant drug is given 
2.  Next position the head and neck as per normal tracheal intubation by 
keeping the neck flexed and head extended by pushing the head from behind 
with one hand while inserting LMA into the mouth with the other hand 
3. While inserting, hold the LMA like a pen with the index finger placed 
anteriorly on the junction of the cuff and the airway tube. Then press it 
against the hard palate and verify whether it lies flat against the palate and 
that the tip is not folded over before further pushing into the pharynx 
4. Now use the index finger to push the LMA backwards with continuously 
maintaining pressure against the palate 
5. When the LMA is pushed downwards, the index finger must maintain a 
backward pressure against the posterior pharyngeal wall to avoid collision 
with the epiglottis. It is necessary to insert the index finger fully into the 
mouth to complete insertion and keep the other fingers out of the mouth 
6. Next check the black line on the tube to face the upper lip and immediately 
inflate the cuff with the recommended volume without holding the tube. It is 
necessary that the cuff should be Inflated before connecting to the circuit so 
that the device can position itself correctly and adequately to obtain the low 
 
 
 
pressure seal. During inflation of the cuff we should not hold the tube as this 
will prevent the device from settling in the correct location. 
7. Then connect to the circuit by holding the tube to prevent any 
displacement.  Now gently inflate the lungs to check for the correct 
placement and confirm it. Insert a roll of gauze as a bite block and tape the 
device into place so that the proximal end of the tube is pointing caudally. 
The tube would be pressed back against the palate and posterior pharyngeal 
wall if it is correctly placed. 
The following are the signs of correct placement of LMA: 
1. Upon inflation of the LMA there will be a slight outward movement of the 
tube 
2. A small oval swelling will be present in the neck around the thyroid and 
cricoid area  
3. There will be no cuff visible in the oral cavity 
4. There will be expansion of the chest wall on ventilation 
 
There are other methods of inserting the laryngeal mask airway (LMA) like  
(a) Reverse technique (180o rotation) 
(b) Fully or partially inflated cuff 
(c) Techniques based on different head positions 
(d) Laryngoscope guided LMA insertion 
(e) Yodfat technique 
 
 
 
(f) Using an introducer 
(g) Insertion in prone position. 
Manoeuvres which can aid in LMA insertion: Jaw thrust, Chin-lift, anterior 
traction of tongue, superior laryngeal nerve block, partial removal or 
insertion. 
Complications of LMA (50) 
• The most common complication of laryngeal mask Airway is the post-
operative sore throat.  Excessive pressure or malposition off the cuff can be 
exacerbated by incorrect mask size use of nitrous oxide and prolonged 
surgery. To avoid this the most important factor to be monitored is the 
intraoperative cuff pressure which  if maintained constantly drastically 
reduces the incidence of sore throat in the postoperative period 
• Trauma to the pharyngeal cavity, airway edema and arytenoid dislocation is 
not uncommon. Rarely hypoglossal nerve injury, numbness of the tongue 
secondary to lingual nerve injury, recurrent laryngeal nerve injury and vocal 
cord paralysis may occur. Usually the nerve injuries are because of the wrong 
positioning of the LMA or excessive cuff pressure. 
• If the patient is under light sedation during surgical stimulation or if bronchial 
secretions irritate the vocal cords during emergence from anaesthesia, 
laryngeal spasm may occur.  LMA should not be removed if laryngeal spasm 
occurs. LMA should be removed only when  Airway protective  reflexes are 
fully competent 
 
 
 
 
Induction techniques for LMA insertion 
Intravenous induction: Many drugs are used either alone or in 
combination for induction in the intravenous route which is by far the 
preferred route in most of the conditions. The following drugs have been used 
for IV induction for LMA insertion (51, 52, and 53): 
• Propofol 
• Thiopentone 
• Etomidate 
• Etomidate + propofol 
• Fentanyl + propofol 
• Ketamine+ propofol 
 
Inhalational induction: Sometimes in infants and children where IV 
access is not possible, inhalational induction is the preferred route. The 
following drugs have been used for inhalational induction for LMA insertion 
(54, 55, and 56): 
• Sevoflurane 
• Sevoflurane + propofol 
 
 
 
 
 
 
 
Propofol 
Propofol is a 2, 6 diisopropyl phenol and it has become one of the most 
frequently used intravenous anaesthetics today. It has a rapid onset 
predictable half-time and provides rapid emergence from anaesthesia (57, 58, 59). 
Also it has a favourable side effect profile and antiemetic property which aids 
in many conditions including induction and maintenance of general 
anaesthesia, Intensive Care units (ICU) sedation and as a sedative-hypnotic in 
the context of outpatient procedures. 
 
Drug structure of propofol 
Commercial preparation  
Propofol is an insoluble drug that requires lipid vehicle for 
Emulsification and the current formulations usually use soybean oil as the oil 
phase and egg lecithin as an emulsifying agent which contains long chain 
triglycerides. This commercial formulation causes raised plasma triglyceride 
 
 
 
levels when prolonged IV infusions are used and also it supports bacterial 
growth (60, 61, 62, 63). 
A generic formulation of propofol incorporates sodium metabisulphite 
as the preservative and has a lower PH between 4.5 to 6.4 whereas Diprivan 
uses the disodium edetate as a preservative with sodium hydroxide to bring 
the pH between 7 to 8.5. 
Like thiopental, etomidate and ketamine, propofol is also not a clinical 
compound. Propofol cannot be mixed with any other drugs as it may result in 
coalescence of oil droplets and may pose a risk of pulmonary embolism 
which can rarely occur when mixed with lidocaine to prevent the pain on IV 
injection (64). 
Propofol should be administered within 6 hours of opening the ampoule as 
sepsis and death have been linked to contaminated propofol preparations. 
Pharmacokinetics  
A. Absorption: Propofol is available only for intravenous administration for 
the induction of anaesthesia and for moderate to Deep sedation 
B. Distribution: The distribution half-life of propofol is 1.3 to 4.1 minutes 
as it is 98% protein bound in the plasma and resulting in a brief duration of 
action following bolus administration of the drug. Propofol distributes itself 
into different compartments in the Alpha phase and three compartment 
models are necessary to study its pharmacokinetics in actuality (65). 
 
 
 
C. Metabolism: Propofol undergoes conjugation to an inactive glucuronide 
in the liver or it may get metabolized to quinol which is excreted as sulphate 
and glucuronide conjugates of the hydroxylated metabolite via cytochrome 
P450 and extra hepatic metabolism also probably contributes as the drug 
clearance exceeds the hepatic blood flow. Fortunately renal and hepatic 
diseases do not have much significant effect on the metabolism of propofol 
(66) 
D. Excretion: The metabolites of propofol are excreted in the urine 
unchanged and the elimination half-life is 9.3 to 69.3 minutes. The clearance 
is much higher in children and it is decreased in the presence of renal failure. 
The terminal elimination half-life maybe prolonged following extended 
administration although under normal conditions propofol is non-cumulative 
(66). 
Mechanism of action 
  Propofol is a relatively selective modulator of Gamma amino butyric 
acid (GABA-A) receptors though its activity is also observed in the glycine 
receptors. The sedative and hypnotic effects of the propofol can be attributed 
to the GABA receptor interaction.  GABA is the principal inhibitory 
neurotransmitter in the brain and when these receptors are activated the trans 
membrane chlorine conductance increases which results in the 
hyperpolarization of the postsynaptic cell membrane and there occurs a 
functional inhibition of postsynaptic neurons (67).  
 
 
 
The interaction of the propofol with specific components of GABA-A 
receptor appears to reduce the rate of dissociation of neurotransmitter which 
is inhibitory in its prime action hence propofol increases the duration of 
GABA activated opening of the chloride channels resulting in the 
hyperpolarization of the cell membranes. In contrast to the other volatile 
anaesthetics propofol does not alter the spinal motor neuron excitability 
which suggests that immobility during propofol anaesthesia is not because of 
drug-induced spinal cord depression (68). 
Effects of propofol on major systems  
A. Effects on cardiovascular system 
 The most important effect on the cardiovascular system is the 
reduction in arterial blood pressure because of the drop in systemic vascular 
resistance (because of the inhibition of sympathetic vasoconstriction), preload 
and cardiac contractility. Moreover propofol causes hypotension following 
induction which is usually compensated by the stimulation accompanying the 
laryngoscopy and intubation. The factors which are associated with the 
propofol induced hypotension include rapid injection of the drug, old age and 
using large doses (69).  In the usual doses propofol impairs the normal arterial 
baro-reflex response to the hypotension. Sometimes there is reduction in 
preload which may lead to reflex bradycardia which is vagally mediated. In 
healthy patients there is a transient and in significant change in heart rate and 
cardiac output but this effect may be significant in patients at extremes of 
age, in patients receiving beta blockers, in patients with impaired ventricular 
 
 
 
function. The coronary sinus lactate production increases in some patients 
though the myocardial oxygen consumption and coronary blood flow usually 
decreases which demonstrates that there is some mismatch between the 
myocardial oxygen supply and demand (70). 
B. Effects on the respiratory system 
  There is a profound respiratory depression which usually causes apnea 
following an induction dose of propofol. There is inhibition of hypoxic 
ventilation drive and also depresses the normal response to hypercarbia even 
when used in sub-anaesthetic doses for conscious sedation (71). When 
compared to thiopental there is greater depression of upper Airway reflexes 
with propofol and hence alloying intubation, endoscopy or laryngeal mask 
airway placement in the absence of neuromuscular blockade. Induction with 
propofol is associated with lower incidence of wheezing in asthmatic patients 
and non-asthmatic patients when compared with barbiturates or   etomidate 
even though propofol is known to cause release of histamine (72). 
C. Effects on the central nervous system 
  Cerebral blood flow and intracranial pressure decreases with 
administration of propofol in patients with increased intracranial tension / 
pressure, propofol can cause critical reduction of CPP (<50 mm Hg) which 
necessitates measures to be taken to support the mean arterial blood pressure. 
In circumstances of experimental focal ischemia, propofol and thiopentone 
provide a similar degree of cerebral protection but propofol is unique in its 
anti-pruritic property. Propofol also has a antiemetic effect which is usually 
 
 
 
manifested if blood propofol concentration is above 200 ng / ml and hence 
propofol remains the preferred drug for outpatient anaesthesia. Sometimes 
Induction with propofol call can be accompanied with excitatory phenomena 
such as spontaneous movement, opisthotonus, muscle twitching or hiccups.  
Though this excitatory phenomenon can mimic tonic-clonic seizures, 
propofol also has anticonvulsant property which is used successfully to 
terminate status epilepticus and hence propofol can be safely administered 
even to epileptic patients. The other advantage of propofol is that it decreases 
intraocular pressure. Tolerance does not develop after long term propofol 
infusions and hence propofol is an uncommon agent of physical dependence 
or addiction. 
Side effect profile 
  The most common side effect when propofol is administered 
peripherally is pain on injection which occurs in approximately 60 to 70% of 
the patients and numerous interventions have been tried and tested to 
minimise this side effect. The most   efficient technique to reduce the pain on 
injection following protocol is pre-treatment with the local anaesthetics like 
lidocaine in conjunction with venous occlusion using a tourniquet or effect of 
a modified Bier block.  Antecubital vein should be used as an alternative to 
smaller peripheral veins to minimise the pain on injection. Other techniques 
which are efficient in reducing the pain on injection include free treatment 
with opiates, addition of lidocaine, lowering the propofol concentration by 
diluting the emulsion and changing the lipid solvent (73). 
 
 
 
 Propofol related infusion syndrome (PRIS) is a potential deadly side 
effect of propofol which is extremely rare and it was first described in 
children in the late 90s and subsequently in the adults after its use for 
sedation in the ICU. The clinical features of PRIS include metabolic acidosis, 
hyperkalaemia, hyperlipidaemia, rhabdomyolysis, hepatomegaly, renal 
failure, arrhythmias, major ECG changes and progression to cardiac failure.  
The pathophysiology of PRIS is unclear even today and it is proposed 
that it may involve mitochondrial toxicity which uncouples the intracellular 
respiratory chain.  Some researchers hypothesize that propofol related 
infusion syndrome is because of the indication of fatty acid oxidation (74). 
 The clinical manifestation of PRIS is always dose dependent and duration 
dependent. Short duration infusion of high doses has been associated with 
cardiac failure. The case fatality rate in PRIS cases is above 50 %.  In 2006 
the FDA recommended the maximum propofol infusion dose to be 4 mg / kg 
/ hr. 
 Sometimes there is production of green urine which is reported 
especially in ICU settings following prolonged infusions of propofol.  It is 
stipulated that increased extra hepatic metabolism of propofol and excretion 
of the metabolites in urine causes greenish discoloration (75).  
Allergic reactions are common with propofol and patients who 
develop anaphylaxis on first exposure maybe previously sensitized to 
diisopropyl side chain. Propofol induced bronchoconstriction has been 
 
 
 
described in patients with history of atopy/allergy and in patients with history 
of other drug allergies especially to neuromuscular blocking drugs (75). 
  Propofol does not trigger malignant hyperthermia and can be 
administered to patients with hereditary coproporphyria.  Also secretion of 
cortisol is not affected by group of all even when administered for prolonged 
period or duration there is temporary abolition of tremors in patients with 
Parkinsonism after administration of propofol and hence it may not be suited 
for patients undergoing stereotactic neurosurgery during which the symptom 
is required to correctly identify the anatomic location (75).  
Etomidate 
  It is a carboxylated imidazole and it is chemically unrelated to any 
other drug used for intravenous induction of anaesthesia. The imidazole 
nucleus makes the etomidate to be water soluble like midazolam at an acidic 
pH and lipid soluble at physiologic pH (76). 
Commercial preparations 
  The conventional formulation contain the 35 % propylene glycol 
which contributed for high incidence of pain during an intravenous injection  
 
 
 
 
 
 
 
 
Drug Structure of Etomidate 
 
                            
and occasional venous irritation. Recently it has been changed to fat emulsion 
which has virtually abolished the pain on injection and venous irritation. But 
the incidence of myoclonus remains unchanged even in the new formulation. 
Oral formulation of etomidate for administration through trans-mucosal route 
has shown to provide dose-dependent sedation. The administration in this 
route results in direct systemic absorption while bypassing the hepatic first 
pass metabolism which results in higher blood concentrations achieved at 
much rapid rate compared to the drug being swallowed (76). 
Pharmacokinetics 
A. Absorption: Etomidate is available only for intravenous administration 
for the induction of anaesthesia and it is sometimes used for production of 
unconscious sedation in circumstances such as prior to the placement of retro 
bulbar blocks 
B. Distribution:  etomidate is highly protein bound but it is characterized 
by a very rapid onset of action because of the higher lipid solubility and large 
 
 
 
non-ionized fraction at physiological pH.  The decrease in plasma 
concentration to awakening levels is mainly because of the redistribution of 
the drug.  Because of the redistribution, the pharmacokinetics of the drug can 
be explained only by a two Compartment model (77)  
C. Biotransformation:    The hepatic microsomal enzymes and plasma 
hepatic esterases rapidly hydrolyze etomidate to an inactive metabolite 
D. Excretion: The metabolites of etomidate are excreted in the urine 
unchanged.  
Mechanism of action 
  The unique factor about etomidate among all the injected and 
inhalational anaesthetic agents is that it is being administered as a single 
isomer.  The most important isomeric form which is responsible for 
anaesthetic effect of etomidate is predominantly R + isomer.  This R + isomer 
is approximately 5 times as potent S - isomer.  Unlike barbiturates etomidate 
appears to be relatively selective modulator of Gamma amino butyric acid 
(GABA-A) receptors. Etomidate binds to the GABA-A receptors directly at 
specific sites on the protein and enhances the affinity of the inhibitory 
neurotransmitter GABA for these receptors.  The antagonistic effect of 
steroid induced psychosis demonstrated by etomidate is because of the 
enhancement of GABA receptor function.  Etomidate is not a modulator of 
other ligand gated Ion channels in the brain at usual concentrations. 
Etomidate depresses the reticular activating system and it also mimics the 
inhibition of GABA.  Etomidate exhibits disinhibition on the parts of central 
 
 
 
nervous system that control extrapyramidal motor activity and these results in 
30 to 60 % incidence of myoclonus with etomidate induction of anaesthesia 
(78). 
Effects of etomidate on major systems (79)  
A. Effects on cardiovascular system 
Etomidate has very minimal effects on the cardiovascular system which is 
manifested as and mild reduction in peripheral vascular resistance.  This 
results in slight decrease in arterial pressure whereas the myocardial 
contractility and cardiac output usually remains unchanged.  Etomidate is not 
known to release histamine. Analgesia is not produced by etomidate. For this 
reason, opioid administration before induction with etomidate may be useful 
to blunt hemodynamic responses by laryngoscopy. 
B. Effects on the respiratory system  
When compared with barbiturates or benzodiazepines, etomidate is 
relatively safe as ventilation is least affected even in doses used for induction 
do not usually result in apnea unless opiates are pre-administered 
C. Effects on the central nervous system  
There is a decline in cerebral metabolic rate, cerebral blood flow and 
intracranial pressure.  Because of the minimal cardio-vascular effect, CPP is 
well maintained and sometimes changes on EEG resemble those of 
barbiturates, etomidate increases the amplitude of somatosensory evoked 
potentials. Etomidate do not have any antigenic properties. Postoperative 
 
 
 
nausea and vomiting is very common with etomidate administration when 
compared to propofol or Barbiturates. 
D. Effects on the endocrine system  
Even with usual doses of etomidate used for induction, there is a transient 
inhibition of enzymes involved in cortisol and aldosterone synthesis because 
of the adrenocortical suppression exhibited by etomidate.  Long term infusion 
of etomidate is associated with increased mortality among the critically ill 
patients mainly because of the adrenocortical suppression 
Side effects 
The most important adverse effect of etomidate is the adrenocortical 
suppression. Etomidate exhibits inhibitory action against the enzyme 11 Beta 
hydroxylase and prevents the conversion of cholesterol to cortisol.  Even one 
dose of etomidate is sufficient enough to transiently suppress the 
adrenocortical axis.  Some studies suggest curtailing this effect by pre-
treatment with dexamethasone.  However some researchers concluded that 
there is no direct effect on outcomes following bolus administration of 
etomidate even in high-risk septic population (80).  
25 to 50 % of the patients experience pain on injection and the 
incidence of this pain is decreased by addition of lignocaine.  Myoclonus can 
occur in patients without premeditations. 
 
 
 
 
 
 
The following table shows the comparison between propofol and 
etomidate regarding the hemodynamic changes in percentage (%) after 
induction of anaesthesia 
Parameter Etomidate Propofol 
Heart rate -5 ± 10 -10 ± 10 
Mean arterial blood 
pressure 
0 to 17 -10 – 40 
Systemic vascular 
resistance 
-10 ± 14 -15 – 25 
Pulmonary artery 
pressure 
-9 ± 8 0 – 10 
Pulmonary vascular 
resistance 
-18 ± 6 0 – 10 
Pulmonary artery 
occluded pressure 
Unchanged Unchanged 
Right atrial pressure Unchanged 0 – 10 
Cardiac Index -20 ± 14 -10-30 
Stroke volume 0 - 20 -10-25 
Left ventricular stroke 
work index 
0 - 33 -10-20 
 
 
 
 
 
 
 
 
The following are the studies related to hemodynamic changes 
during LMA insertion 
Balasubramaniam S et al (81) compared the hemodynamic responses 
between laryngeal mask airway (LMA) and endotracheal tube (ETT) 
intubation in a single blinded randomised controlled trial with 60 
normotensive individuals who were posted for elective surgeries under 
general anaesthesia. They divided the samples into two groups with 30 in 
each group and studied the heart rate, blood pressure and rate pressure 
product. These hemodynamic parameters were studied at baseline, pre- 
intubation, 1, 2, 3, 5 and 10 minutes after extubation. They concluded that 
there was a steady increase in hemodynamic responses in both the groups but 
the mean increase in heart rate, blood pressure and rate pressure product was 
significantly lower (p<0.05) for the LMA group in comparison to the 
endotracheal tube group. 
Renu Bala et al (82) assessed the hemodynamic changes with insertion 
of three different supraglottic devices such as classical LMA, proseal LMA 
and I-gel in a prospective randomised study with the sample of 150 patients 
undergoing surgery with ASA status of I and II under general anaesthesia. 
The subjects were divided into three groups of 50 patients each and standard 
anaesthesia protocol with propofol, vecuronium, isoflurane, nitrous oxide and 
fentanyl was followed. Changes in heart rate and blood pressure during 
insertion and removal of the devices was monitored and recorded at various 
 
 
 
time intervals. They concluded that all the three supraglottic devices do not 
differ in hemodynamic changes but I-gel has a higher success rate in 
comparison to classic LMA and proseal LMA. 
Jarineshin H et al (83) compared the immediate hemodynamic effects 
of insertion of supreme LMA and classic LMA with laryngoscopy and 
endotracheal intubation by studying a sample of 150 patients and observing 
the hemodynamic parameters such as heart rate and blood pressure before 
and after induction of anaesthesia. They concluded that the systolic blood 
pressure and diastolic blood pressure was significantly lower in the 
endotracheal tube group in comparison to the LMA group 5 minutes after the 
insertion of device. However there was no significant difference between 
classic LMA and supreme LMA in terms of hemodynamic parameters 
Singh D et al (84) compared the hemodynamic changes during 
insertion and removal of LMA and intubating laryngeal mask airway in a 
prospective randomised study. They compared two groups of 50 patients each 
undergoing elective surgical procedures and they observed that in comparison 
to the baseline there was no significant difference in mean arterial pressure 
and heart rate during insertion and removal of LMA but there was significant 
difference in rate pressure product and during removal there was increase in 
heart rate, mean arterial pressure and rate pressure product. They concluded 
that LMA offers some advantages over intubating LMA in patients with 
 
 
 
coronary artery disease and cerebrovascular disease where minimal changes 
in hemodynamics are desirable. 
The following are the studies related to the use of drugs etomidate 
and propofol for induction 
 Liu et al (85) explored the preventive effect of pre-treatment with 
propofol on etomidate related myoclonus in a prospective double-blind 
randomised controlled study with the sample of 363 patients scheduled for 
painless GI endoscopy. The subjects were divided into 5 groups with one 
group receiving etomidate alone and 3 groups receiving incremental doses of 
propofol pre-treatment before etomidate anaesthesia and fifth group receiving 
1 to 2 mg / kg of propofol for anaesthesia. They are observed that incidence 
of myoclonus in the propofol group was less than the etomidate alone group 
and the incidence of hypoxemia in the propofol group was higher than the 
etomidate alone group whereas the incidence of adverse effects in the 
proposal + etomidate group was lower than the etomidate alone group. 
 Meng Q  et al (86) Compare the safety and efficacy of etomidate and 
propofol anaesthesia in elderly patients posted for gastroscopy in a double-
blinded randomised control study with 200 volunteers randomly allocated to 
propofol alone group, etomidate alone group, propofol followed by etomidate 
group and etomidate followed by propofol group. The result of 3 groups (E, 
P+E and E+P) showed improved hemodynamic stability compared with 
Group P alone (p>0.05). They concluded that the recovery and discharge time 
 
 
 
in the etomidate alone group was significantly higher in comparison to other 
groups and hence propofol in combination with etomidate is a safe and 
effective alternate for elderly patients. 
 Price et al (87) studied the changes in cardiac index and systemic 
vascular resistance during induction of anaesthesia with thiopentone, 
propofol, methohexitone and etomidate in a sample of 90 subjects randomly 
allocated to four groups to receive alfentanil followed by thiopentone, 
methohexitone, propofol or etomidate to obtund the eyelash reflex. They 
concluded that the cardiac stability of etomidate is not so complete in all 
groups of patients as there was significant decrease in cardiac index of 16 % 
among patients who received etomidate alone. 
 Kumar et al (88) compared the effects of propofol and etomidate on 
hemodynamic parameters during the LMA insertion in a prospective 
randomised control study of 60 subjects posted for elective surgery under 
general anaesthesia. The subjects were divided into two groups and in one 
group induction were done with propofol 2.5 mg/ kg and in another group 
induction was done with etomidate 0.3 mg / kg.  They observed that 
etomidate is hemodynamically more stable compared to propofol as the 
reduction in mean systolic and diastolic blood pressure along with mean 
arterial pressure was significantly higher in propofol group but the heart rate 
was comparable in both groups. 
 
 
 
 Agarwal et al (89) compared propofol and etomidate for its 
hemodynamic effects and adverse effects on 100 patients posted for surgeries 
under general anaesthesia.  The samples were divided into two groups with 
one group receiving propofol 2 mg / kg and another group receiving 
etomidate 0.3 mg / kg.  They observed that patients in etomidate group had 
little change in mean arterial pressure and heart rate compared to propofol 
group and myoclonus activity was higher in etomidate group whereas pain on 
injection was more in propofol group. They concluded that etomidate is a 
better alternate agent for induction than propofol. 
Meena et al (22) compared to the effectiveness of three different 
anaesthesia induction approaches in the form of propofol alone (2.5mg/kg), 
etomidate alone (0.3 mg/kg) and propofol (1mg/kg) in combination with 
etomidate (0.2 mg/kg) for maintenance of hemodynamic stability during 
induction and following endotracheal intubation. They studied 90 patients of 
either sex posted for elective surgeries and observed the hemodynamic 
parameters at different time intervals. They observed that heart rate decreased 
in all study groups after induction but it was significantly higher in propofol 
group compared to other groups and after intubation heart rate increased in 
all the three groups whereas mean arterial pressure in all the groups 
decreased after induction and this reduction was higher in propofol group 
than other groups. They concluded that combination therapy with propofol 
and etomidate provides a better hemodynamic stability than either drug 
administered alone. 
 
 
 
Aghdaii et al (90) evaluated the hemodynamic effects of midazolam 
with etomidate by comparing it with propofol and ketamine combination for 
the induction of anaesthesia in 100 patients with left ventricular dysfunction 
undergoing coronary artery bypass graft surgery.  The patients were 
randomly allocated into two groups to receive either propofol and ketamine 
or etomidate with midazolam. They found that the hemodynamic response 
was comparable in both the groups except for cardiac index after one minute 
and 3 minute of intubation. 
Yagan et al (91) measured the hemodynamic responses between use of 
etomidate and propofol in combination and the use of both the drugs 
separately by dividing the subjects into three groups. They observed a 
significant reduction in mean arterial pressure values after intubation in the 
propofol group when compared to etomidate alone group and the 
combination group.  They concluded that propofol-etomidate combination is 
a very good alternative when extremes of hypotensive and hypertensive 
responses are expected. 
Kaushal et al (92) studied the hemodynamic instability and attenuation 
of stress response in patients undergoing cardiac surgery with various 
intravenous anaesthetic agents.  They observed that etomidate provides more 
stable hemodynamic parameters in comparison to propofol and therefore 
etomidate can be safely used for induction in patients with good left 
ventricular function. 
 
 
 
Kaur et al (93) studied the induction and recovery characteristics along 
with hemodynamic parameters of etomidate-lipuro and propofol-lipuro in a 
prospective randomized double-blinded study with 60 cardiac patients of 
either sex. They observed the incidence of Apnea and pain on injection and 
induction time was less in etomidate group than propofol group but 
myoclonus and postoperative nausea and vomiting was more common in 
etomidate group.  The mean systolic blood pressure after 15 minutes and 
mean diastolic blood pressure after 5 minutes was lower in propofol group 
when compared to etomidate group which led them to conclude that 
etomidate is a better alternative to propofol in cardiac patients to attain 
hemodynamic stability and faster induction. 
Hosseinzadeh H et al (16) evaluated the hemodynamic effects of 
ketamine and propofol (group A) in comparison to etomidate and propofol 
(group B) for anaesthesia induction. They studied a total of 60 patients above 
50 years of age posted for elective surgeries with Group A receiving 
ketamine 0.75 mg / kg and propofol 1 mg / kg and Group B receiving 
etomidate 0.2 mg /kg and propofol 1 mg / kg.  They observed that there was a 
significant reduction in systolic, diastolic and mean arterial pressure after 
induction and after 6 minutes of intubation in both the groups and hence they 
concluded that both the methods of induction are effective to maintaining 
hemodynamic stability. 
Hosseinzadeh H et al (94) compare the three methods of induction of 
anaesthesia namely propofol, etomidate in combination propofol and  
 
 
 
etomidate alone with regards to hemodynamic stability after insertion of 
laryngeal mask airway in elective surgeries. About 90 patients were divided 
into three groups with 30 subjects in each group. Group A received propofol 
2.5 mg / kg, group B received etomidate 0.3 mg / kg and Group C received 
propofol 1 mg / kg plus etomidate 0.2 mg / kg. They observed heart rate, 
systolic, diastolic blood pressure and mean arterial pressure before induction 
and 30 minutes after induction. They also noted the number of attempts for 
laryngeal mask Airway insertion and the ease of placement of LMA in all the 
three groups. They observe the significant difference in hemodynamic 
changes between group A in comparison to group B and Group C. They also 
noted that heart rate was lower in group A and group B besides the number of 
 attempts and   ease of insertion was significantly  different in group B when 
compared to group A and Group C they concluded that  etomidate Plus 
propofol is effective for facilitating LMA insertion with an advantage of 
cardiovascular stability . 
Hashaam B et al (95) compared the hemodynamic effects of etomidate 
with propofol for insertion of laryngeal mask airway in a prospective 
randomized double-blinded study among patients undergoing elective 
surgeries under general anaesthesia. All the patients were administered where 
given IV fentanyl and either etomidate or propofol as an induction agent after 
which LMA was inserted in 30 seconds. They observed that there was no 
difference in heart rate between the two groups however there was a 
significant drop in systolic blood pressure in propofol group in comparison to 
 
 
 
etomidate group while fall in diastolic blood pressure was observed in both 
groups.  About 93% of the patients in propofol group had successful insertion 
of LMA in the first attempt in comparison to 36.7% in etomidate group.  
They concluded that etomidate for induction of laryngeal mask anaesthesia 
can prevent hypotension but delay the insertion of LMA. 
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MATERIALS AND METHODS 
STUDY AREA 
 The study was conducted among the patients posted for elective 
surgeries in Department of Anaesthesiology, Government Theni Medical 
College & Hospital, Theni.  
STUDY POPULATION 
 The study population included 90 patients posted for elective surgeries 
like  
• Fibroadenoma Breast - Excision  
• Gynaecomastia – Webster’s procedure  
• Duration of surgery less than 30 minutes (Subareolar Cyst Removal, Cervical 
Adenitis - Excision Biopsy, Hysteroscopic Endometrial Sampling and 
Metacarpal bone fracture - K Wire Fixation). 
 
 
  
 
 
 
 
 
 
 
TIMELINE 
 The study work is described in detail in the following Henry Gantt chart from its inception to the completion.  
       Activity 
2016 2017 2018 
8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 
Protocol 
preparation, 
Submission  
                    
   
Questionnaire 
Preparation,  
Ethical 
clearance 
                    
   
Data Collection           
 
Data Entry & 
Analysis 
               
Thesis 
finalization 
                   
 
 
 
 
 
STUDY PERIOD 
The data collection for the study was done between May 2017 to September 
2018. 
SAMPLE SIZE 
 Based on the literature (22), to discover a 10 unit change in BP/PR (α=0.05, 
β=0.2 and power=0.08) sample size of 90 was considered. 
GROUP A- Etomidate 0.2 mg/kg + Propofol 0.5 mg/kg (30) 
GROUP B- Etomidate 0.2 mg/kg + Propofol 1 mg/kg (30) 
GROUP C- Etomidate 0.2 mg/kg + Propofol 1.5 mg/kg (30) 
 So the total sample size was considered as 90. 
INCLUSION CRITERIA 
1. Either gender 
2. Age between 20-60 years 
3. ASA I and II 
4. Elective surgeries like  
➢ Fibroadenoma Breast - Excision  
➢ Gynaecomastia – Webster’s procedure  
➢ Duration of surgery less than 30 minutes (Subareolar Cyst Removal, Cervical Adenitis 
- Excision Biopsy, Hysteroscopic Endometrial Sampling and Metacarpal bone fracture 
- K Wire Fixation). 
 
 
 
 
 
EXCLUSION CRITERIA 
1. Individuals who did not give consent. 
2. Pregnancy 
3. Alcohol and drug abusers 
4. Patients allergic to drugs involved in the study 
5. Cardiovascular  diseases  
6. Respiratory diseases 
7. Significant Neurological illnesses like Epilepsy 
8. Hepatic and Renal diseases 
9. Emergency surgeries 
10.  BMI > 30 
11.  ASA III and IV  
12.  Anticipated difficult intubation such as MPG III, IV and Thyromental distance < 
6.5cm, Mouth opening < 2.5 cm. 
13.  Existence of a considerable pathology in the larynx or pharynx 
STUDY DESIGN 
 It was a double blinded randomized clinical trial. 
SAMPLING DESIGN 
 Systematic random sampling design was applied in the current study. 
 
 
 
 
 
 
 
STUDY TECHNIQUE 
The following flow chart shows an overview of thesis from inception to submission. 
 
 
 
 
 
 
 
METHODOLOGY  
1. Patients were kept overnight fasting and were premedicated with T.Alprazolam 0.5mg 
and T.Ranitidine 150mg on the night day before surgery. 
2. All patients were preloaded with Ringer Lactate (6ml/kg)  
3. 18 gauge IV cannula was secured.  
4. Standard anaesthesia monitors including Electrocardiogram (ECG), Non Invasive 
Blood Pressure (NIBP) and Pulse Oximeter were attached and Baseline Hemodynamic 
parameters were recorded. 
5. Inj. Glycopyrrolate (0.01 mg/kg) iv was given. 
6. Preoxygenation done for 3minutes with 100% oxygen. 
7. Midazolam 0.025mg/kg iv, Fentanyl 2microgram/kg iv, and Lidocaine 1mg/kg IV was 
given. 
8. Patients were randomly assigned to one of three groups. 
9. GROUP A patients received - Etomidate 0.2 mg/kg + Propofol 0.5 mg/kg.  
GROUP B patients received - Etomidate 0.2 mg/kg + Propofol 1 mg/kg  
GROUP C patients received - Etomidate 0.2 mg/kg + Propofol 1.5 mg/kg  
10. All study drugs were prepared by Anaesthesiologist who had been blinded to the 
details of the study. 
11. The volume of the medications (20 ml) and the speed of the injection (30 seconds) 
were equal in all three groups.  
12. Prior to induction, 30 seconds and 60 seconds after induction, hemodynamic variables 
were recorded.  
 
 
 
 
13. 60 seconds after loss of consciousness (which was confirmed by inability to reply to 
verbal commands and loss of eyelash reflex), appropriate size of Classical LMA 
insertion was done with partially inflated technique by Second Anaesthesiologist. 
14. Proper placement of LMA was assessed by chest expansion and capnography. The 
success rate of LMA insertion was evaluated based on the ventilation status. 
15. Ease of ventilation was defined as the presence of normal capnogram wave and lack of 
air leak after LMA insertion. 
16. In case of poor ventilation, LMA was removed and reinserted. A rescue Propofol dose 
of 1mg/kg was used whenever there was resistance to LMA insertion or the patient 
moved. 
17. Patient was excluded from the study in case of failure in LMA insertion after second 
attempt. 
18. Duration of LMA insertion [from the period of insertion of LMA to the checking of 
bilateral air entry] was recorded.  
19. Following successful LMA insertion, connected to close circuit and Duration of apnea 
was noted. 
20. Anaesthesia was maintained by equal mixture of Oxygen – Nitrous Oxide (4 litre per 
minute), sevoflurane 0.8% and along with intermittent bolus of Non-Depolarizing 
Muscle Relaxant (Atracurium) as required throughout the surgery. 
21. Hemodynamic parameters like Blood pressure (Systolic, Diastolic and Mean Arterial 
Pressure), Heart rate and oxygen saturation were recorded at 1min, 3min, 5min, 7min 
and 10min after induction. 
22. At the end of the surgery residual neuromuscular block was reversed with Inj. 
Neostigmine (0.05 mg/kg IV) and Inj. Glycopyrrolate (0.01 mg/kg IV). 
 
 
 
 
23. LMA was removed after adequate recovery of muscle power. 
24. Side effects like Pain on injection, Hypotension (>20% reduction), Bradycardia 
(HR<60), Post-operative nausea, vomiting (PONV) and Myoclonus was noted. 
25. Complications in LMA Insertion like Coughing, Gag reflex, Laryngospasm was noted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STUDY PARAMETERS 
1. Blood pressure (Systolic, Diastolic and Mean Arterial Pressure) - [prior to induction, 
30 seconds, 60 seconds, 1min, 3min, 5min, 7min and 10min after induction]. 
2. Heart rate [prior to induction, 30 seconds, 60 seconds, 1min, 3min, 5min, 7min and 
10min after induction]. 
3. Spo2 [prior to induction, 30 seconds, 60 seconds, 1min, 3min, 5min, 7min and 10min 
after induction]. 
4. Ease of LMA Insertion [number of attempts (1/ 2/ >2), duration (in seconds) of 
LMA Insertion]. 
5. Duration of Apnea. 
6. Side effects [Pain on injection, Hypotension (>20% reduction), Bradycardia (HR<60), 
Post-operative nausea vomiting (PONV) and Myoclonus]. 
7. Complications in LMA Insertion [Cough, Gag reflex and Laryngospasm]. 
 
 
 
 
 
 
 
 
 
 
 
STATISTICAL ANALYSIS 
All the data was initially entered to Microsoft Excel 2010 and later these 
spreadsheets were used for analysis. Statistical analysis was done using SPSS version 
22.0.  
1. DESCRIPTIVE STATISTICS 
Descriptive statistics were calculated as frequency, percentage, mean and standard 
deviation, median and inter-quartile range. Descriptive data were represented using 
various tables, graphs, diagrams etc.  
2. INFERENTIAL STATISTICS 
For inferential statistics, various tests of significance were used according to the type 
of variables dealt with. For all the statistical tests of significance, p value of <0.05 was 
considered to reject the null hypothesis. Chi square test was used to compare the 
various categorical variables. To reduce the error in approximation, Yates’s correction 
for continuity is used. Factorial Repeated Measures ANOVA was used to compare 
between the 3 groups. Post hoc analysis with Bonferroni correction for multiple 
comparison was performed when statistically significant differences were observed in 
the Repeated Measures Analysis. 
 
3. TESTS FOR NORMALITY 
Shapiro –Wilk Test and Kolmogorov Smirnov Tests were used to test whether the data 
follow normal distributions or not. Since the test was statistically not significant 
 
 
 
 
(p=0.679 i.e. p>0.05), the data follow a normal distribution, and Parametric tests were 
used.  
4. SIGNIFICANCE LEVEL 
For all the statistical tests of significance, p value of <0.05 was considered to reject the 
null hypothesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
Table 1: Age distribution of the study population (n=90) 
 
Age group Frequency Percent 
11 - 20 years 10 11.1 
21 - 30 years 42 46.7 
31 - 40 years 26 28.9 
41 - 50 years 9 10 
51 - 60 years 3 3.3 
Total 90 100.0 
 
Mean Age (± S.D):  30.07 (± 8.95) years 
 
 
Minimum: 16 years  maximum: 53 years 
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Table 2: Comparison of age among the three study groups (n=90) 
Group N 
Mean 
age 
(years) 
Std. Deviation 
95% Confidence Interval for Mean 
Lower Bound Upper Bound 
A 30 32.82 9.250 26.60 39.03 
B 30 28.32 6.111 25.37 31.26 
C 30 30.29 11.698 23.53 37.04 
Total 90 30.07 8.956 27.35 32.79 
 
 
ANOVA test was applied to test the difference in mean age between the groups. 
 
 
ANOVA TEST 
 
p value 0.422 
F statistic 0.882 
Degree of 
freedom 
2 , 41 
 
 
               ANOVA test showed that there was no statistically significant difference in 
mean age between the groups and hence all the 3 groups were comparable. 
 
 
 
 
 
 
 
 
 
Table 3: Comparison of gender distribution among the study groups (n=90) 
Group 
Female 
N (%) 
Male 
N (%) 
Total 
N (%) 
A 
20 
(29.4) 
10 
(45.5) 
30 (33.3) 
B 
25 
(36.7) 
5 (22.7) 30 (33.3) 
C 
23 
(33.9) 
7 (31.8) 30 (33.3) 
Total 
68 
(100) 
 22 
(100) 
100 (100) 
 
Chi-square value: 1.646  p value: 0.439 
       Gender distributions of subjects in the three groups were comparable and the 
minimal difference observed was not statistically significant. 
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Table 4: Comparison of weight among the three study groups (n=90) 
Group N 
Mean 
weight 
(kg) 
Std. Deviation 
95% Confidence Interval for Mean 
Lower Bound Upper Bound 
A 30 55.00 7.457 49.99 60.01 
B 30 54.26 5.733 51.50 57.03 
C 30 55.14 7.263 50.95 59.34 
Total 90 54.73 6.543 52.74 56.72 
 
ANOVA test was applied to test the difference in mean weight between the groups. 
 
 
ANOVA TEST 
 
p value 0.671 
F statistic 0.082 
Degree of 
freedom 
2 , 41 
 
 
         
ANOVA test showed that there was no statistically significant difference in mean 
weight between the groups and hence all the 3 groups were comparable. 
 
 
 
 
 
 
 
 
 
Table 5: Comparison of diagnosis among the study groups (n=90) 
Diagnosis 
A 
N (%) 
B 
N (%) 
C 
N (%) 
Total 
N (%) 
Fibroadenoma Breast 18 (60) 24 (80) 20 (66.7) 62 (68.9) 
Gynaecomastia 5 (16.7) 3 (10) 4 (13.3) 12 (13.3) 
Others 7 (23.3) 3 (10) 6 (20) 16 (17.8) 
Total 30 (100)  30 (100) 30 (100) 90 (100) 
 
Chi-square value: 8.372  p value: 0.212 
         The difference in diagnosis observed between three groups was not statistically 
significant. 
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Table 6: Comparison of ASA risk among the study groups (n=90) 
Group ASA I 
N (%) 
ASA II 
N (%) 
Total 
N (%) 
A 
27 
(33.7) 
3 (30) 
30 
(33.3) 
B 
26 
(32.6) 
4 (40) 
30 
(33.3) 
C 
27 
(33.7) 
3 (30) 
30 
(33.3) 
Total 
80 
(100) 
10 (100) 
90 
(100) 
 
Chi-square value: 2.757 p value: 0.252 
         Distribution of subjects according to ASA risk was comparable in the three 
groups and the minimal difference observed was not statistically 
significant.
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Table 7: Group-wise comparison of systolic blood pressure at various time 
periods (n=90) 
 Group Mean SBP 
Std. 
Deviation 
N 
SBP 
Baseline 
A 125.27 7.938 30 
B 119.58 12.130 30 
C 135.50 19.114 30 
Total 126.07 15.311 90 
SBP 
30 sec 
A 119.27 15.563 30 
B 115.58 10.151 30 
C 121.00 15.772 30 
Total 118.23 13.437 90 
SBP 
60 sec 
A 121.09 19.279 30 
B 119.84 19.288 30 
C 119.86 13.928 30 
Total 120.16 17.353 90 
SBP 
3 min 
A 117.82 18.449 30 
B 114.89 19.064 30 
C 118.50 21.198 30 
Total 116.77 19.234 90 
SBP 
5 min 
A 120.55 17.840 30 
B 123.95 16.102 30 
C 121.29 15.097 30 
Total 122.25 15.930 90 
SBP 
7 min 
A 128.45 21.727 30 
B 131.74 18.058 30 
C 128.00 13.405 30 
Total 129.73 17.429 90 
SBP 
10 min 
A 133.18 20.808 30 
B 135.79 18.615 30 
C 128.93 15.583 30 
Total 132.95 18.111 90 
 
 
 
 
 
 
Factorial- Repeated measures ANOVA was applied to test the difference in mean 
systolic blood pressure at various time intervals between the three groups. 
Model 
Systolic blood 
pressure 
Systolic blood pressure * 
Group 
Wilks’s 
Lambda  
0.414 0.602 
df 6,36 12,72 
p value <0.001 0.041 
 
 
Between 3 groups - Systolic blood pressure 
F statistic 1.156 
df 2,41 
p value 0.0473 
 
 
 
Post-Hoc Test for SBP (n=90) 
 
Time interval Group A vs Group B Group A vs Group C Group B vs Group C 
Baseline vs 30 sec 0.781 0.048 0.027 
Baseline vs 3 min 0.652 0.038 0.033 
Baseline vs 10 min 0.374 0.043 0.045 
 
 
 
 
 
 
 
 
 
 
 
       There was statistically significant difference in the systolic blood pressure over 
time at 30 sec, 3 min and 10 min as suggested above and also statistically significant 
difference in changes of SBP over time between the three groups [Group A vs Group C 
and Group B vs Group C ] with (P = 0.0473)  
 
 
 
 
 
 
 
 
Table 8: Group-wise comparison of diastolic blood pressure at various time 
periods (n=90) 
 Group Mean DBP 
Std. 
Deviation 
N 
DBP 
Baseline 
A 79.64 7.775 30 
B 78.63 9.038 30 
C 83.79 10.998 30 
Total 80.52 9.490 90 
DBP 
30 sec 
A 78.91 9.843 30 
B 75.00 10.541 30 
C 77.00 11.381 30 
Total 76.61 10.524 90 
DBP 
60 sec 
A 78.27 13.907 30 
B 78.58 14.743 30 
C 75.29 8.818 30 
Total 77.45 12.718 90 
DBP 
3 min 
A 76.91 11.256 30 
B 73.47 16.681 30 
C 75.00 13.021 30 
Total 74.82 14.111 90 
DBP 
5 min 
A 82.18 11.771 30 
B 80.58 12.686 30 
C 79.43 10.775 30 
Total 80.61 11.652 90 
DBP 
7 min 
A 86.27 14.711 30 
B 88.00 14.810 30 
C 81.00 11.456 30 
Total 85.34 13.831 90 
DBP 
10 min 
A 86.73 10.946 30 
B 90.79 15.580 30 
C 80.86 11.568 30 
Total 86.61 13.727 90 
 
 
 
 
 
 
 
Factorial- Repeated measures ANOVA was applied to test the difference in mean 
diastolic blood pressure at various time intervals between the three groups. 
Model 
Diastolic blood 
pressure 
Diastolic blood 
pressure * 
Group 
Wilks’s Lambda  0.570 0.735 
df 6,36 12,72 
p value 0.002 0.043 
 
Between 3 groups - Diastolic blood pressure 
F statistic 1.252 
df 2,41 
p value 0.045 
 
 
Post-Hoc Test for DBP (n=90) 
 
Time interval Group A vs Group B Group A vs Group C Group B vs Group C 
Baseline vs 30 sec 0.048 0.035 0.019 
Baseline vs 7 min 0.912 0.044 0.027 
Baseline vs 10 min 0.561 0.049 0.034 
 
 
 
 
 
 
 
       There was statistically significant difference in the diastolic blood pressure over 
time at 30 sec, 7 min and 10 min as suggested above and also statistically significant 
difference in changes of DBP over time between the three groups [Group A vs Group 
B, Group A vs Group C and Group B vs Group C ] with (P = 0.045). 
 
 
 
 
 
 
 
 
Table 9: Group-wise comparison of mean arterial pressure at various time 
periods (n=90) 
 Group Mean MAP 
Std. 
Deviation 
N 
MAP 
Baseline 
A 94.09 5.924 30 
B 90.05 10.788 30 
C 100.93 14.323 30 
Total 94.52 11.880 90 
MAP 
30 sec 
A 89.73 9.961 30 
B 86.84 9.935 30 
C 93.07 15.214 30 
Total 89.55 11.902 90 
MAP 
60 sec 
A 93.45 13.209 30 
B 89.42 15.214 30 
C 91.21 10.657 30 
Total 91.00 13.209 90 
MAP 
3 min 
A 88.09 11.929 30 
B 86.63 17.072 30 
C 91.00 14.905 30 
Total 88.39 15.029 90 
MAP 
5 min 
A 93.91 11.640 30 
B 96.68 13.933 30 
C 93.86 13.248 30 
Total 95.09 12.954 90 
MAP 
7 min 
A 97.73 15.589 30 
B 100.42 16.504 30 
C 95.00 12.070 30 
Total 98.02 14.836 90 
MAP 
10 min 
A 99.82 12.197 30 
B 104.42 16.153 30 
C 96.57 12.513 30 
Total 100.77 14.248 90 
 
 
 
 
 
 
Factorial- Repeated measures ANOVA was applied to test the difference in mean 
arterial pressure at various time intervals between the three groups. 
Model 
Mean arterial 
pressure 
Mean arterial 
pressure * 
Group 
Wilks’s Lambda  0.520 0.640 
df 6,36 12,72 
p value <0.001 0.024 
 
 
Between 3 groups - Mean arterial pressure 
F statistic 1.044 
df 2,41 
p value 0.014 
 
 
Post-Hoc Test for MAP (n=90) 
 
Time interval Group A vs Group B Group A vs Group C Group B vs Group C 
Baseline vs 30 sec 0.718 0.024 0.016 
Baseline vs 7 min 0.582 0.039 0.512 
Baseline vs 10 min 0.673 0.027 0.019 
 
 
 
 
 
 
 
           There was statistically significant difference in the mean arterial pressure over 
time at 30 sec, 7 min and 10 min as suggested above and also statistically significant 
difference in changes of MAP over time between the three groups [Group A vs Group 
C and Group B vs Group C ] with (P = 0.014). 
 
 
 
 
 
 
 
 
 
 
Table 10: Group-wise comparison of pulse rate at various time periods 
(n=90) 
 Group Mean PR Std. Deviation N 
Pulse rate 
Baseline 
A 86.55 15.162 30 
B 85.11 15.797 30 
C 81.57 10.530 30 
Total 84.34 13.980 90 
Pulse rate 
30 sec 
A 89.09 14.515 30 
B 90.47 16.290 30 
C 85.29 10.395 30 
Total 88.48 14.069 90 
Pulse rate 
60 sec 
A 86.73 12.410 30 
B 94.16 18.836 30 
C 84.93 9.311 30 
Total 89.36 15.129 90 
Pulse rate 
3 min 
A 89.00 14.262 30 
B 88.79 18.201 30 
C 82.71 11.684 30 
Total 86.91 15.351 90 
Pulse rate 
5 min 
A 86.82 13.482 30 
B 85.37 21.474 30 
C 78.86 9.984 30 
Total 83.66 16.637 90 
Pulse rate 
7 min 
A 83.00 12.050 30 
B 84.47 20.359 30 
C 80.57 10.449 30 
Total 82.86 15.593 90 
Pulse rate 
10 min 
A 86.55 11.970 30 
B 91.37 18.643 30 
C 78.50 9.485 30 
Total 86.07 15.399 90 
 
 
 
 
 
 
 
Factorial- Repeated measures ANOVA was applied to test the difference in mean pulse 
rate at various time intervals between the three groups. 
Model Mean pulse rate 
Mean pulse rate 
* Group 
Wilks’s Lambda  0.670 0.646 
df 6,36 12,72 
p value 0.019 0.012 
 
 
Between 3 groups - Mean pulse rate 
F statistic 1.197 
df 2,41 
p value 0.008 
 
 
Post-Hoc Test for pulse rate (n=90) 
 
Time interval Group A vs Group B Group A vs Group C Group B vs Group C 
Baseline vs 60 sec 0.981   0.920 0.009 
Baseline vs 5 min 0.487 0.024 0.021 
Baseline vs 10 min 0.557 0.017 0.044 
 
 
 
 
 
 
             There was statistically significant difference in the mean pulse rate over time at 
60 sec, 5 min and 10 min as suggested above and also statistically significant 
difference in changes of MPR over time between the three groups [Group A vs Group 
C and Group B vs Group C ] with (P = 0.008). 
 
 
 
 
 
 
 
 
Table 11: Group-wise comparison of oxygen saturation at various time 
periods (n=90) 
 
 
Group 
Mean SpO2 Std. 
Deviation 
 
N 
SpO2 
Baseline 
A 99.64 .809 30 
B 99.89 .315 30 
C 99.86 .535 30 
Total 99.82 .540 90 
SpO2 
30 sec 
A 99.82 .603 30 
B 99.95 .229 30 
C 100.00 .000 30 
Total 99.93 .334 90 
SpO2 
60 sec 
A 99.91 .302 30 
B 99.89 .459 30 
C 100.00 .000 30 
Total 99.93 .334 90 
SpO2 
3 min 
A 99.82 .405 30 
B 100.00 .000 30 
C 99.93 .267 30 
Total 99.93 .255 90 
SpO2 
5 min 
A 99.73 .467 30 
B 100.00 .000 30 
C 99.14 3.207 30 
Total 99.66 1.817 90 
SpO2 
7 min 
A 99.64 .674 30 
B 100.00 .000 30 
C 100.00 .000 30 
Total 99.91 .362 90 
SpO2 
10 min 
A 99.45 .688 30 
B 100.00 .000 30 
C 100.00 .000 30 
Total 99.86 .409 90 
 
 
 
 
 
 
Factorial- Repeated measures ANOVA was applied to test the difference in mean 
oxygen saturation at various time intervals between the three groups. 
Model 
Mean SpO2 
Mean SpO2* 
Group 
Wilks’s Lambda  0.726 0.591 
df 6,36 12,72 
p value 0.059 0.064 
 
 
 
Between 3 groups – Mean SpO2 
F statistic 2.015 
df 2,41 
p value 0.146 
 
 
 
 
 
 
           There was no statistically significant difference in the mean oxygen saturation 
over time as suggested above also there was no statistically significant difference in 
changes of oxygen saturation over time between the three groups. 
 
 
 
 
 
 
 
 
 
 
Table 12: Comparison of number of attempts for LMA insertion among the 
study groups (n=90) 
Group 
1 attempt 
N (%) 
2 attempts 
N (%) 
Total 
N (%) 
A 26 (31.7) 4 (50) 
30 
(33.3) 
B 28 (34.1) 2 (25) 
30 
(33.3) 
C    28 (34.1) 2 (25) 
30 
(33.3) 
Total 82 (100)  8 (100) 
100 
(100) 
Chi-square value: 0.764 p value: 0.682 
 
 
Distribution of subjects according to number of attempts for LMA insertion was 
comparable in the three groups and the minimal difference observed was not 
statistically significant. 
 
 
 
 
 
Table 13: Comparison of time taken for LMA insertion among the three 
study groups (n=90) 
Group N 
Mean 
Time for LMA 
(seconds) 
Std. Deviation 
95% Confidence Interval for 
Mean 
Lower 
Bound 
Upper Bound 
A 30 14.36 8.34 8.76 19.96 
B 30 13.75 6.87 7.63 17.56 
C 30 12.43 4.95 6.58 16.11 
Total 90 13.51 6.72 7.66 17.87 
 
ANOVA test was applied to test the difference in mean time taken for LMA insertion 
between the groups.                                       
                                                        
 
ANOVA TEST 
 
p value 0.258 
F statistic 1.399 
Degree of 
freedom 
2 , 41 
 
 
 
 
 
 
 
 
 
ANOVA test showed that there was no statistically significant difference in mean time 
taken for LMA insertion between the groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 14: Comparison of duration of apnea among the three study groups 
(n=90) 
Group N 
Mean 
Duration of apnea 
(seconds) 
Std. Deviation 
95% Confidence Interval for 
Mean 
Lower 
Bound 
Upper Bound 
A 30 99.09 103.000 29.89 168.29 
B 30 112.16 102.418 46.85 180.99 
C 30 134.36 147.198 49.37 219.35 
Total 90 115.20 117.538 42.03 189.54 
 
 
ANOVA test was applied to test the difference in mean duration of apnea between the 
groups. 
 
ANOVA TEST 
 
p value 0.595 
F statistic 0.526 
Degree of 
freedom 
2 , 41 
 
 
 
 
 
 
 
 
 
ANOVA test showed that duration of apnea was higher in the C group in comparison 
to the other groups. But this difference was not statistically significant between the 
groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 15: Comparison of side effects among the study groups (n=90) 
Group Pain on 
injection 
N (%) 
Hypotension 
N (%) 
Myoclonus 
N (%) 
Bradycardia 
N (%) 
 
  PONV 
N (%) 
Total 
N (%) 
A 0 (0) 1 (25) 2 (100) 0 (0) 0 (0) 30 (33.3) 
B 0 (0) 1 (25) 0 (0) 0 (0) 0 (0) 30 (33.3) 
C 0 (0) 2 (50) 0 (0) 0 (0) 0 (0) 30 (33.3) 
Total 0 (0) 4 (100) 2 (100) 0 (0) 0 (0) 100 (100) 
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          Hypotension was seen 2 patients of Group C and one patient of each Group A & 
B. Myoclonus was seen only in 2 patients of Group A. 
 
 
 
 
 
 
 
 
Table 16: Comparison of complications in LMA insertion among the study 
groups (n=90) 
Group 
Cough 
N (%) 
Gag reflex 
N (%) 
Laryngospasm 
N (%) 
Total 
N (%) 
A 1 (100) 0 (0) 0 (0) 30 (33.3) 
B 0 (0) 0 (0) 0 (0) 30 (33.3) 
C 0 (0) 0 (0) 0 (0) 30 (33.3) 
Total 1 (100) 0 (0) 0 (0) 100 (100) 
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Among the study population, cough was seen in only one patient of Group A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
GENERAL CONSIDERATIONS 
 The result of the present study demonstrated that there is improved 
hemodynamic stability and minimal respiratory depression when propofol is 
administered along with etomidate, instead of either of this agents used alone for 
anaesthesia during elective surgeries. Co-administration of propofol and etomidate has 
a favorable side effects profile, allowed rapid recovery to full activity and provides 
high levels of patient satisfaction. (86) 
 The laryngeal mask has been shown to be an effective means of securing clean 
airway during surgeries. Its insertion does not require penetration of larynx, thereby 
making the placement less stimulating than tracheal tube insertion or extubation. (81) 
Hemodynamic changes associated with LMA insertion are similar to those of guedel’s 
airway and less than those with SLIPA. (82) 
DISTRIBUTION OF DEMOGRAPHIC VARIABLES 
 Highest percentage 42 (46.7%) of study population were in the age group of 21-
30 years, 26 (28.9%) were in the age between 31-40 years, 10 (11.1%) in the age group 
of 11-20 years, 9 (10%) in the age between 41-50 years and 3 (3.3%) were in the age 
group of 51-60 years. 
 With regard to comparison of age among three study groups, the highest mean 
age for Group A mean (M) was 32.82, standard deviation (SD) ± 9.250, for Group B 
was 28.32 ± 6.111 and for Group C it was 30.29 ± 11.689. 
 
 
 
 
 Regarding percentage distribution of study population according to their gender 
showed that 68 (68%) were female and 22 (22%) were male. 
 In comparison of weight among three study groups, the mean weight in Group 
A was 55.00 ± 7.457, for Group B was 54.26 ± 5.733 and for Group C it was 55.14 ± 
7.263. 
Regarding comparison of diagnosis, the most common diagnosis was 
Fibroadenoma Breast 62 (68.9%), others were 16 (17.8%) and Gynaecomastia was 12 
(13.3%).  
In comparison of ASA risk among the study sample, Group A and Group C had 
highest 27 (33.7%) ASA I risk and 3 (30%) ASA II risk, Group B had ASA I risk 26 
(30.6%) and ASA II risk was 4 (40%). 
ANOVA test showed that there was no statistical significant difference in mean 
age, gender distribution, weight, diagnosis and ASA risk between three groups and 
hence all the three groups were comparable. 
INTERPRETATION AND COMPARISON OF FINDINGS OF SYSTOLIC 
BLOOD PRESSURE, DIASTOLIC BLOOD PRESSURE AND MEAN 
ARTERIAL PRESSURE 
 The study findings revealed that there was statistical significant difference in the 
systolic blood pressure over time at 30 sec, 3 min and 10 min and also statistically 
significant difference in changes of SBP over time between the three groups [Group A 
vs Group C and Group B vs Group C ] with (P = 0.0473). In this study Group A and 
 
 
 
 
Group B, systolic blood pressure change was not seen much due to minimal dosage of 
drugs than Group C.  
 This study findings are consistent with the study conducted by Hosseinzadeh et 
al (94) among 90 patients with ASA Classes I and II undergoing elective surgeries were 
selected and the results showed that there is a significant difference in hemodynamic 
(systolic blood pressure) changes between Group 1 in comparison with Group 2 and 
Group 3. This study findings are consistent with the study conducted by Jarineshin H 
et al (83) concluded that the systolic blood pressure was significantly lower in the 
endotracheal tube group in compare to the laryngeal mask airway groups in 5 minutes 
after the insertion of device. Other study supports this finding includes, Meng Q et al 
(86) results of 3 groups (E, P+E and E+P) showed improved hemodynamic stability 
compared with group P alone (P>0.05). 
The present study showed that there was statistically significant difference in 
the diastolic blood pressure over time at 30 sec, 7 min and 10 min and also statistically 
significant difference in changes of DBP over time between the three groups [Group A 
vs Group B, Group A vs Group C and Group B vs Group C ] with (P = 0.045). 
This study findings are consistent with the study conducted by Hosseinzadeh et 
al (94) among 90 patients with ASA Classes I and II undergoing elective surgeries were 
selected and the results showed that there is a significant difference in hemodynamic 
(diastolic blood pressure) changes between Group 1 in comparison with Group 2 and 
Group 3. This study findings are consistent with the study conducted by Jarineshin H 
et al (83) concluded that the diastolic blood pressure was significantly lower in the 
endotracheal tube group in compare to the laryngeal mask airway groups in 5 minutes 
 
 
 
 
after the insertion of device. Kumar et al (88) concluded that etomidate is 
hemodynamically more stable compared to propofol as the reduction in mean diastolic 
blood pressure was significantly higher in propofol. 
The present study showed that there was statistically significant difference in 
the mean arterial pressure over time at 30 sec, 7 min and 10 min and also statistically 
significant difference in changes of MAP over time between the three groups [Group A 
vs Group C and Group B vs Group C ] with (P = 0.014). 
This study findings are consistent with the study conducted by Meena et al (22) 
with 90 patients who were posted for elective surgery under general anaesthesia. The 
results showed that mean arterial pressure (MAP) among all three groups got decreased 
after induction and it was high in Group 1 than Group II and III. Significant increase in 
MAP was seen at 1 minute after intubation in all three groups but this was not 
sustained and returned to baseline in Group II and III. This study findings are 
consistent with the study conducted by Agarwal et al (89) observed that patients in 
etomidate group had little change in mean arterial pressure compared to propofol 
group. Kumar et al (88) concluded that etomidate is hemodynamically more stable 
compared to propofol as the reduction in mean arterial pressure was significantly 
higher in propofol. 
INTERPRETATION AND COMPARISON OF FINDINGS OF MEAN 
PULSE RATE 
The present study revealed that there was statistically significant difference in 
the  mean pulse rate over time at 60 sec, 5 min and 10 min and also statistically 
 
 
 
 
significant difference in changes of  pulse rate over time between the three groups 
[Group A vs Group C and Group B vs Group C ] with (P = 0.008). 
This study finding contradicts with the study conducted by Meena et al (22) with 
90 patients who were posted for elective surgeries under general anaesthesia. The 
results showed that heart rate (HR) in all study group decreases after induction and it 
was more in Group I compared to Group II and III (P<0.000) and after intubation HR 
increases in all three groups but this increase is greater in Group II than other two 
groups.  
INTERPRETATION AND COMPARISON OF OXYGEN SATURATION 
The present study showed that there was no statistically significant difference in 
the mean oxygen saturation over time and also there was no statistically significant 
difference in changes of oxygen saturation over time between the three groups. 
This study findings are consistent with the study conducted by Meena et al (22) 
with 90 patients who were posted for elective surgery under general anaesthesia. The 
results showed that there was no statistical difference seen among three groups in terms 
of oxygen saturation. This study finding contradicts with the study performed by Liu et 
al (85) observed that the incidence of hypoxemia in the propofol group was higher that 
the etomidate alone group.  
INTERPRETATION AND COMPARISON OF EASE OF LMA 
INSERTION 
 
 
 
 
The present study findings revealed that number of attempts for LMA insertion 
was comparable in the three groups and the minimal difference observed was not 
statistically significant. 
The present study results showed that there was no statistically significant 
difference in mean time [For Group A (14.36 ± 8.34) sec, Group B (13.75 ± 6.87) sec 
and Group C (12.43 ± 4.95) sec] taken for LMA insertion between the groups. 
This study finding contradicts with the study conducted by Hosseinzadeh et 
al(94) among 90 patients participated in this study and the results showed that there was 
significant difference in the number of attempts and ease of LMA insertion between 
Group II in compare with Group I and III. This study finding contradicts with another 
study conducted by Hashaam B et al (95) concluded that 93% of patients in propofol 
group had successful insertion of LMA in the 1st attempt in compare to 36.7% in 
etomidate group. The study concludes that ease for induction of laryngeal mask 
anaesthesia can prevent hypotension but delays insertion of LMA. 
INTERPRETATION AND COMPARISON OF DURTION OF APNEA 
 The present study revealed that the duration of apnea was higher in Group C 
(134.36 ± 147.198) sec, whereas it was (112.16 ± 102.418) sec in Group B and (99.09 
± 103.000) sec in Group A. 
This study findings are consistent with the study conducted by Hosseinzadeh et 
al (94) among 90 patients participated in this study and the duration of apnea in Group 2 
was (8.67 ± 6) min, whereas it was (18.10 ± 6.25) min in Group 1 and (12.03 ± 6.4) 
min in Group 3.  
 
 
 
 
INTERPRETATION AND COMPARISON OF SIDE EFFECT OF 
DRUGS 
 The study findings showed that in Group A, the most common side effect 
observed was myoclonus 2 (100%) and in Group C it was hypotension 2 (50%). This 
study findings are consistent with the study performed by Liu et al (85) observed that the 
incidence of myoclonus in the propofol group was less than the etomidate group alone, 
whereas the incidence of adverse effects in the propofol +etomidate group was lower 
that the etomidate group alone. Agarwal et al (89) found that myoclonus activity was 
high in etomidate group whereas pain on injection was more in propofol group.  
INTERPRETATION AND COMPARISON OF COMPLICATIONS IN 
LMA INSERTION 
The present study findings revealed that the complication during LMA insertion 
in Group A had cough 1 (100%) and the remaining Group B and Group C had no 
complications.  
 
 
 
 
 
 
                                                
 
 
 
 
 
SUMMARY 
The present study was conducted with the aim to compare the Hemodynamic 
parameters during LMA Insertion with same dose of Etomidate and varying doses of 
Propofol among patients posted for elective surgeries in Department of 
Anaesthesiology, Government Theni Medical College & Hospital, Theni. Totally 90 
patients posted for elective surgeries such as Fibroadenoma Breast – Excision, 
Gynaecomastia – Webster’s procedure and Duration of surgery less than 30 minutes 
(Subareolar Cyst Removal, Cervical Adenitis - Excision Biopsy, Hysteroscopic 
Endometrial Sampling and Metacarpal bone fracture - K Wire Fixation) were selected 
those who fulfill the inclusion criteria. Double blinded randomized clinical trial study 
design was adopted. The study design selected for this study was systematic random 
sampling. The protocol was prepared based on the guidelines. Ethical clearance was 
obtained from the Institutional Ethical Committee. Informed consent was obtained 
after explaining the purpose of the study. The data was collected from May 2017 to 
September 2018. The study population was divided into 3 groups in which GROUP A- 
was administered with Etomidate 0.2 mg/kg + Propofol 0.5 mg/kg (30), GROUP B- 
Etomidate 0.2 mg/kg + Propofol 1 mg/kg (30) and GROUP C- Etomidate 0.2 mg/kg + 
Propofol 1.5 mg/kg (30). Hemodynamic parameters like Blood pressure (systolic, 
diastolic and mean arterial pressure), Heart rate and Oxygen saturation were recorded 
at Base line, 30sec, 60sec, 1min, 3min, 5min, 7min and 10min after induction. The 
success rate of LMA insertion was evaluated based on the ventilation status. Duration 
of LMA insertion [from the period of insertion of LMA to the checking of bilateral air 
entry] was recorded. Following successful LMA insertion, connected to close circuit 
and Duration of apnea was noted. Side effects like Pain on injection, Hypotension 
 
 
 
 
(>20% reduction), Bradycardia (HR<60), Post-operative nausea, vomiting (PONV) 
and Myoclonus was noted. Complications in LMA Insertion like Cough, Gag reflex, 
Laryngospasm was observed.  
❖ Results showed that there was no statistical significant difference in mean age, gender 
distribution, weight, diagnosis and ASA risk between three groups and hence all the 
three groups were comparable.  
❖ In systolic blood pressure there was statistical significant difference in changes of SBP 
over time between the three groups [Group A vs Group C and Group B vs Group C] 
with (P = 0.0473).  
❖ In diastolic blood pressure there was statistical significant difference in changes of 
DBP over time between the three groups [Group A vs Group B, Group A vs Group C 
and Group B vs Group C ] with (P = 0.045).  
❖ In mean arterial pressure there was statistical significant difference in changes of MAP 
over time between the three groups [Group A vs Group C and Group B vs Group C] 
with (P= 0.014).  
❖ In mean pulse rate there was statistical significant difference in changes of MPR over 
time between the three groups [Group A vs Group C and Group B vs Group C] with (P 
= 0.008).  
❖ There was no statistical difference found in terms of oxygen saturation, number of 
LMA attempts and duration of LMA insertion. 
 
 
 
 
❖ The present study revealed that the duration of apnea was higher in Group C (134.36 ± 
147.198) sec, whereas it was (112.16 ± 102.418) sec in Group B and (99.09 ± 103.000) 
sec in Group A. 
❖ The study findings showed that in Group A, the most common side effect observed was 
myoclonus 2 (100%) and in Group C it was hypotension 2 (50%). 
❖ The present study findings revealed that the complication during LMA insertion in 
Group A had cough 1 (100%) and the remaining Group B and Group C had no 
complications.  
 
 
 
 
 
 
 
 
 
 
 
 
                                            
 
 
 
 
 
 
CONCLUSION 
                 Results of this study suggest that Group A (Etomidate 0.2mg/kg + Propofol 
0.5 mg/kg) and Group B (Etomidate 0.2mg/kg + Propofol 1 mg/kg) regimens provides 
desirable hemodynamic stability following insertion of LMA than Group C (Etomidate 
0.2mg/kg + Propofol 1.5 mg/kg). In addition to the favorable side effect profile, airway 
maintenance and respiratory depression was similar in all three groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                              
 
 
 
 
LIMITATIONS 
 
❖ This study excluded the patients with airway problems, as these patients require longer 
intubation time, which can result in different outcomes. 
❖ This study was conducted on patients with ASA I and II. Making such comparisons on 
patients with underlying cardiac diseases may bring out different results. 
❖ Depth of anaesthesia was not monitored in the study. 
❖ Plasma corticosteroid concentrations were not measured. 
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ANNEXURE II 
MASTER SHEET 
S.No Name IP.No Age Sex Weight Diagnosis ASA 
Risk 
Group SBP 0 SBP 
30sec 
SBP 
60sec 
SBP 
3min 
SBP 
5min 
SBP 
7min 
SBP 
10min 
1.  Vanitha 20782 20 F 48 F 1 A 132 139 128 140 144 159 155 
2.  Nivitha 20952 24 F 54 F 1 A 114 107 100 92 100 109 116 
3.  Suga priya 20490 24 F 62 F 1 A 134 136 130 142 146 161 157 
4.  suruliyammal 21230 32 F 55 F 1 A 123 118 148 119 116 115 120 
5.  Roja 24069 26 F 51 F 1 A 121 116 148 117 114 113 118 
6.  Laxmi 33328 35 F 68 F 1 A 129 105 96 105 120 128 126 
7.  Sasikala 26120 39 F 42 F 1 A 110 90 120 100 110 120 130 
8.  Sheeja 27646 42 F 50 F 1 A 131 109 101 93 97 102 95 
9.  Shanthi 30430 50 F 60 F 1 A 132 126 135 130 132 137 159 
10.  Janaki 22742 29 F 53 O 1 A 130 132 126 138 142 157 153 
11.  Loganathan 36618 40 M 62 O 1 A 122 134 100 120 105 112 136 
12.  Ramadevi 20960 21 F 62 F 1 B 123 123 115 111 121 153 162 
13.  Bommu 21238 22 F 54 F 1 B 118 111 104 96 104 113 121 
14.  Karpagavalli 72839 25 F 49 F 1 B 132 131 144 158 146 165 159 
15.  Venila 23290 25 F 56 F 1 B 115 113 120 129 144 136 134 
16.  Chitradevi 20845 26 F 54 F 1 B 112 142 148 150 142 128 141 
17.  Jeyamani 22463 28 F 55 F 1 B 120 120 112 108 118 150 159 
18.  Vinitha 25272 19 F 52 F 1 B 122 100 98 99 116 115 100 
19.  Sobana 26454 20 F 43 F 2 B 107 116 104 98 96 98 115 
20.  Renuka 38269 25 F 65 F 1 B 128 110 120 110 120 124 118 
21.  Thavamani 37733 26 F 62 F 1 B 128 112 146 122 132 128 136 
22.  Asma 31696 33 F 52 F 1 B 100 103 110 129 130 142 150 
23.  Dhanalaksmi 26789 34 F 48 F 1 B 146 123 117 90 138 136 133 
24.  Sundarammal 31336 36 F 56 F 1 B 113 124 100 103 110 130 142 
 
 
 
 
25.  Kanagavalli 33783 39 F 60 F 1 B 116 109 102 94 102 111 118 
26.  Vijayalaxmi 37486 39 F 56 F 1 B 133 116 163 124 131 146 152 
27.  Asma 31646 33 F 52 A 1 B 100 103 110 124 130 142 150 
28.  Eswari 20798 27 F 45 O 1 B 121 116 137 122 144 131 138 
29.  Vidhya 26486 28 F 52 O 1 B 105 109 99 92 99 103 104 
30.  Madhurakani 25468 32 F 58 O 2 B 133 115 128 124 132 152 148 
31.  Sivarani 21917 21 F 50 F 1 C 127 97 121 129 123 118 114 
32.  Sridevi 21720 23 F 52 F 1 C 162 135 117 103 118 142 146 
33.  Suganyadevi 23375 25 F 57 F 1 C 111 114 109 127 130 125 127 
34.  Maheswari 20441 25 F 48 F 1 C 160 145 160 171 147 142 145 
35.  Amsavalli 23972 27 F 75 F 1 C 139 138 126 146 154 145 137 
36.  Tamil selvi 20637 29 F 52 F 1 C 131 101 125 133 127 122 118 
37.  Jayalakshmi 20563 36 F 65 F 1 C 136 115 111 114 113 109 104 
38.  Gowsalya 25282 16 F 50 F 1 C 114 106 114 92 106 126 118 
39.  Indrani 42861 35 F 58 F 1 C 120 109 108 108 111 124 128 
40.  Palaniyammal 34996 45 F 54 F 1 C 122 112 126 112 116 122 132 
41.  Rani 30862 53 F 54 F 1 C 131 139 100 99 96 103 103 
42.  Gokul doss 30046 17 M 48 O 1 C 118 116 124 117 119 128 139 
43.  Umameena 73753 23 F 53 O 1 C 160 133 116 101 116 140 144 
44.  Mookammal 30530 49 F 56 O 1 C 166 134 121 107 122 146 150 
45.  Selvi 9135 32 F 48 F 1 A 122 116 108 122 126 140 158 
46.  Muthumari 9157 36 F 54 F 1 A 102 96 90 96 102 116 130 
47.  Balamurugan 9012 37 M 62 G 2 A 114 106 102 112 116 122 134 
48.  Priya 9136 18 F 42 O 1 A 104 98 92 104 108 118 126 
49.  Muthulakshmi 9255 22 F 58 F 1 A 102 94 88 98 102 116 132 
50.  Ravi 8841 35 M 64 G 1 A 112 106 98 116 122 142 156 
51.  Mukila 8481 25 F 56 O 2 A 114 106 100 108 112 124 136 
52.  Murugeshwari 9212 27 F 53 F 1 A 124 118 110 118 124 132 146 
53.  Nandhini 9202 16 F 45 F 1 A 122 116 106 120 124 136 150 
54.  Vimala 9227 43 F 53 F 1 A 134 124 116 128 132 142 156 
 
 
 
 
55.  Sathyaseelan 9186 28 M 61 O 1 A 126 120 112 122 124 130 142 
56.  Sathya  9467 23 F 58 F 1 A 112 106 100 110 116 124 136 
57.  Eswari 9426 28 F 55 F 1 A 114 104 96 112 116 126 142 
58.  Thangadurai 10417 38 M 66 G 2 A 102 96 92 106 112 126 132 
59.  Mahesh 10876 26 M 60 O 1 A 106 98 94 108 114 128 142 
60.  Veeramani 10546 52 M 57 O 1 A 114 108 100 110 116 130 144 
61.  Prabha 10362 29 M 61 G 1 A 128 120 116 126 130 142 156 
62.  Anbuselvan 10083 36 M 69 G 1 A 126 122 118 130 136 140 152 
63.  Karthik 10919 22 M 63 O 1 A 116 106 102 116 122 136 150 
64.  Dhanam 11266 28 F 58 F 1 B 112 106 100 108 116 126 140 
65.  Gomathi 11014 35 F 70 O 1 B 114 106 100 106 114 122 138 
66.  Ranjani 11483 25 F 49 F 1 B 124 118 112 122 126 130 140 
67.  Vasanthakumar 11316 18 M 50 G 1 B 122 116 106 118 124 130 142 
68.  Rajesh kumar 11057 29 M 65 O 2 B 134 124 114 126 128 136 140 
69.  Kannan 10957 33 M 58 G 1 B 126 120 110 114 120 126 132 
70.  Vijaya 11649 29 F 64 F 1 B 112 106 100 108 114 120 132 
71.  Karthiga 11540 24 F 61 F 1 B 114 104 96 110 114 122 136 
72.  Kavitha 11652 26 F 57 F 1 B 96 90 84 98 102 110 122 
73.  Selvam 10813 29 M 52 O 1 B 104 98 92 102 104 116 130 
74.  Kalirajan 10918 42 M 66 G 2 B 102 96 90 102 104 112 120 
75.  Panchavarnam 14177 55 F 56 F 2 C 114 106 100 102 106 118 120 
76.  Nivetha 13717 19 F 47 O 1 C 134 124 116 118 126 128 132 
77.  Ponmeena 14166 22 F 49 F 1 C 126 120 112 118 122 126 130 
78.  Arivuselvi 143336 32 F 55 F 1 C 114 104 96 110 112 116 120 
79.  Balaji 14213 31 M 58 G 1 C 96 90 84 92 100 106 112 
80.  Divya 14079 20 F 52 O 1 C 102 96 90 102 104 110 118 
81.  Raman 14309 47 M 68 G 1 C 114 106 104 108 112 116 120 
82.  Raja 14902 29 M 67 O 1 C 122 116 110 120 122 126 130 
83.  Velmurugan 15007 34 M 68 O 1 C 134 124 116 120 122 128 130 
84.  Sekar 26724 25 M 61 G 2 C 106 96 92 98 102 106 110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
85.  Veeralakshmi 15019 34 F 59 F 1 C 114 108 100 106 110 112 116 
86.  Malathi 15095 21 F 55 O 1 C 128 120 116 120 124 126 130 
87.  Muthupetchi 15162 57 F 65 F 2 C 126 122 118 130 134 136 140 
88.  Sivakumar 15337 37 M 68 O 1 C 116 106 102 110 116 120 122 
89.  Thamaraiselvi 14840 42 F 63 F 1 C 114 108 104 110 116 122 124 
90.  Muthuselvi 15370 36 F 59 F 1 C 110 102 96 112 116 120 126 
 
 
 
 
 
S.No Name 
DBP0 
DBP 
30sec 
DBP 
60sec 
DBP 
3min 
DBP 
5min 
DBP 
7min 
DBP 
10min MAP0 
MAP 
30sec 
MAP 
60sec 
MAP 
3min 
MAP 
5min 
MAP 
7min 
MAP 
10min 
1.  Vanitha 88 91 90 87 97 106 94 101 102 102 101 109 119 107 
2.  Nivitha 70 74 59 52 68 71 78 88 84 78 67 81 80 91 
3.  Suga priya 91 93 92 89 99 108 96 103 104 104 103 111 121 109 
4.  suruliyammal 73 73 94 75 79 78 81 87 86 110 86 91 88 95 
5.  Roja 71 71 92 73 77 76 79 85 84 108 84 89 86 93 
6.  Laxmi 84 83 65 83 92 96 88 96 88 70 85 98 106 100 
7.  Sasikala 80 60 70 76 78 86 90 90 70 86 82 92 95 102 
8.  Sheeja 69 76 68 62 65 70 64 94 86 84 71 76 81 73 
9.  Shanthi 81 76 83 83 80 82 105 97 87 100 96 96 97 121 
10.  Janaki 87 89 88 85 95 104 92 99 100 100 99 107 117 105 
11.  Loganathan 82 82 60 81 74 72 87 95 96 86 95 83 85 102 
12.  Ramadevi 88 80 74 66 80 109 118 97 92 85 78 92 123 131 
13.  Bommu 74 78 61 58 72 75 82 92 88 82 71 85 86 95 
14.  Karpagavalli 92 97 95 113 102 110 117 104 106 104 127 116 130 129 
15.  Venila 81 80 84 97 104 101 89 92 91 97 108 116 109 103 
16.  Chitradevi 76 98 102 103 70 83 96 87 113 116 117 99 99 106 
17.  Jeyamani 85 77 71 63 77 106 115 94 89 82 75 89 120 128 
18.  Vinitha 89 62 66 60 72 75 62 101 70 71 68 87 87 72 
19.  Sobana 67 70 61 58 57 55 73 78 83 75 72 71 77 88 
20.  Renuka 84 70 84 70 80 84 78 97 92 85 78 92 96 95 
21.  Thavamani 78 66 92 72 76 82 84 86 82 84 85 90 86 92 
22.  Asma 65 60 75 86 93 95 95 76 77 86 92 110 78 102 
23.  Dhanalaksmi 94 75 72 65 94 85 83 113 85 85 78 111 102 98 
24.  Sundarammal 70 86 65 60 86 93 95 68 76 76 77 92 110 116 
25.  Kanagavalli 72 76 61 56 70 73 80 90 86 80 69 83 84 93 
26.  Vijayalaxmi 86 71 105 81 85 98 102 86 85 125 93 103 114 118 
 
 
 
 
27.  Asma 65 60 75 86 93 95 95 76 77 86 98 110 111 113 
28.  Eswari 80 71 104 70 78 81 84 95 85 117 95 113 98 103 
29.  Vidhya 70 77 69 58 61 70 73 85 88 81 69 73 80 84 
30.  Madhurakani 78 71 77 74 81 102 104 94 85 82 96 105 118 118 
31.  Sivarani 85 64 78 76 74 72 72 100 74 93 95 92 88 87 
32.  Sridevi 96 89 66 65 85 87 90 117 109 88 82 97 104 109 
33.  Suganyadevi 70 77 74 90 88 89 86 81 88 87 102 101 79 99 
34.  Maheswari 90 84 90 98 69 60 62 120 115 120 126 113 85 92 
35.  Amsavalli 93 96 89 99 105 106 91 113 110 102 113 122 120 106 
36.  Tamil selvi 89 68 82 80 78 76 76 104 78 97 99 96 92 91 
37.  Jayalakshmi 88 75 76 73 80 73 68 99 85 87 84 90 84 80 
38.  Gowsalya 67 58 70 56 62 77 79 87 78 88 72 77 105 95 
39.  Indrani 70 66 66 66 75 79 80 87 76 85 85 76 89 90 
40.  Palaniyammal 76 72 82 76 80 86 86 86 82 78 84 86 88 96 
41.  Rani 84 74 65 64 66 68 62 96 100 78 75 76 82 72 
42.  Gokul doss 71 75 82 75 78 89 98 86 88 96 91 92 104 115 
43.  Umameena 94 87 64 63 83 85 88 116 107 86 80 95 102 107 
44.  Mookammal 100 93 70 69 89 91 94 121 113 92 86 101 108 113 
45.  Selvi 74 70 68 64 78 90 86 90 85 81 83 94 106 110 
46.  Muthumari 68 64 60 64 74 78 84 79 78 70 74 83 90 99 
47.  Balamurugan 70 66 62 64 74 82 90 85 73 75 80 91 95 104 
48.  Priya 74 70 66 62 80 92 86 84 79 75 76 89 101 102 
49.  Muthulakshmi 72 68 66 68 78 86 94 82 79 75 78 86 96 107 
50.  Ravi 76 74 68 70 82 92 100 88 84 78 85 89 108 119 
51.  Mukila 80 74 70 72 80 92 98 91 85 80 84 91 103 111 
52.  Murugeshwari 84 78 72 76 84 96 104 97 91 85 90 97 108 118 
53.  Nandhini 74 70 66 68 78 90 92 90 85 79 85 93 105 111 
54.  Vimala 82 76 74 74 84 98 106 99 92 90 92 100 112 122 
55.  Sathyaseelan 72 68 66 68 78 86 94 90 85 81 86 93 101 110 
56.  Sathya  80 74 68 70 82 92 100 91 85 79 83 93 103 112 
 
 
 
 
57.  Eswari 74 68 66 68 78 88 92 87 80 76 83 91 101 109 
58.  Thangadurai 80 74 68 70 82 92 102 87 81 76 82 92 103 112 
59.  Mahesh 68 66 62 64 74 80 92 81 77 73 79 87 96 109 
60.  Veeramani 72 68 66 68 76 84 92 86 81 77 82 89 99 110 
61.  Prabha 74 70 68 64 80 92 86 92 87 84 85 97 109 111 
62.  Anbuselvan 70 66 62 64 74 82 90 89 85 81 86 95 101 112 
63.  Karthik 80 74 68 70 82 92 100 92 85 79 81 95 107 100 
64.  Dhanam 74 70 64 70 72 78 88 87 82 76 83 87 94 105 
65.  Gomathi 82 76 74 74 82 92 96 93 86 83 85 87 95 107 
66.  Ranjani 76 68 66 68 78 80 86 92 85 81 86 94 97 104 
67.  Vasanthakumar 70 66 62 66 80 84 88 87 83 77 83 95 99 100 
68.  Rajesh kumar 68 64 60 64 74 78 80 90 84 78 85 92 97 100 
69.  Kannan 80 74 68 70 82 86 92 95 89 82 85 95 99 105 
70.  Vijaya 68 66 62 64 74 80 86 83 79 75 79 87 93 101 
71.  Karthiga 72 68 66 68 76 84 88 86 80 76 82 89 97 104 
72.  Kavitha 74 70 68 64 80 86 92 81 90 84 75 87 92 98 
73.  Selvam 70 66 62 64 74 78 82 81 77 72 77 84 91 98 
74.  Kalirajan 80 74 68 70 82 92 96 87 81 75 81 89 99 100 
75.  Panchavarnam 72 70 66 62 68 70 74 86 82 71 75 81 86 89 
76.  Nivetha 76 74 68 70 76 80 82 95 91 84 86 93 96 99 
77.  Ponmeena 80 74 70 72 78 82 86 95 85 84 87 93 97 101 
78.  Arivuselvi 74 70 66 68 72 76 80 87 81 76 82 85 89 93 
79.  Balaji 82 76 64 76 82 86 90 86 81 74 71 81 88 93 
80.  Divya 72 68 66 68 74 80 84 82 77 74 79 84 90 95 
81.  Raman 80 74 68 70 72 78 82 91 85 80 93 85 91 95 
82.  Raja 74 68 66 68 72 76 82 90 84 81 85 89 93 98 
83.  Velmurugan 70 66 62 66 72 78 84 91 85 80 84 88 95 99 
84.  Sekar 68 64 60 64 72 78 82 81 75 73 82 85 87 91 
85.  Veeralakshmi 74 70 66 72 74 76 80 87 83 77 83 85 87 92 
86.  Malathi 82 76 74 76 78 84 90 97 91 88 91 95 97 99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
87.  Muthupetchi 76 68 66 68 72 76 82 93 86 83 89 93 96 101 
88.  Sivakumar 70 66 62 66 72 76 80 85 79 75 81 87 91 94 
89.  Thamaraiselvi 68 64 60 64 74 78 82 83 79 75 79 88 93 96 
90.  Muthuselvi 68 66 62 68 76 84 92 82 78 73 83 89 96 103 
 
 
 
 
S.No. Name 
PR0 
PR 
30 
sec 
PR 
60 
sec 
PR 
3 
min 
PR 
5 
min 
PR 
7 
min 
PR 
10 
min SPO20 
SPO2 
30 
sec 
SPO2 
60 
sec 
SPO2 
3min 
SPO2 
5min 
SPO2 
7min 
SPO2 
10min 
Attempts 
For  
LMA 
Duration 
Apnoea 
(seconds) 
1.  Vanitha 71 79 77 91 83 77 83 100 100 100 100 100 100 100 1 90 
2.  Nivitha 70 72 68 62 59 55 58 100 100 100 100 100 100 100 1 360 
3.  Suga priya 73 81 79 93 85 79 85 100 100 100 99 99 99 99 1 30 
4.  suruliyammal 109 106 101 96 95 97 90 100 100 99 100 99 100 100 1 20 
5.  Roja 107 104 99 94 93 95 88 98 98 100 100 100 100 99 1 20 
6.  Laxmi 96 69 86 73 73 82 80 100 100 100 100 100 100 100 1 210 
7.  Sasikala 92 112 102 110 102 88 96 100 100 100 100 100 100 100 1 60 
8.  Sheeja 82 92 87 77 81 83 105 100 100 100 100 99 99 99 1 60 
9.  Shanthi 101 96 102 108 101 95 94 98 100 100 100 100 98 98 1 120 
10.  Janaki 69 77 75 89 81 74 81 100 100 100 99 100 100 99 1 30 
11.  Loganathan 82 92 78 86 102 88 92 100 100 100 100 100 100 100 1 90 
12.  Ramadevi 80 87 113 97 86 73 85 100 99 98 100 100 100 100 1 50 
13.  Bommu 72 74 70 64 61 57 60 100 100 100 100 100 100 100 1 60 
14.  Karpagavalli 61 66 79 86 87 91 94 99 100 100 100 100 100 100 1 60 
15.  Venila 85 77 74 92 78 76 95 100 100 100 100 100 100 100 1 0 
16.  Chitradevi 92 113 110 101 103 97 105 100 100 100 100 100 100 100 1 30 
17.  Jeyamani 77 84 110 94 83 70 82 100 100 100 100 100 100 100 1 20 
18.  Vinitha 88 82 79 79 85 84 81 100 100 100 100 100 100 100 2 60 
19.  Sobana 76 94 91 94 97 93 101 100 100 100 100 100 100 100 1 60 
20.  Renuka 94 102 100 98 94 90 92 99 100 100 100 100 100 100 1 30 
21.  Thavamani 88 86 102 76 68 84 86 100 100 100 100 100 100 100 1 60 
22.  Asma 78 101 92 74 64 78 92 100 100 100 100 100 100 100 1 60 
23.  Dhanalaksmi 125 123 137 127 135 128 122 100 100 100 100 100 100 100 1 180 
24.  Sundarammal 80 74 78 101 96 82 78 100 100 100 100 100 100 100 1 360 
25.  Kanagavalli 70 72 68 62 59 55 58 100 100 100 100 100 100 100 1 360 
26.  Vijayalaxmi 79 76 83 65 59 62 105 100 100 100 100 100 100 100 1 60 
 
 
 
 
27.  Asma 78 101 92 74 64 78 92 100 100 100 100 100 100 100 1 60 
28.  Eswari 111 115 118 113 111 121 120 100 100 100 100 100 100 100 1 60 
29.  Vidhya 73 87 81 76 73 69 67 100 100 100 100 100 100 100 1 50 
30.  Madhurakani 110 105 112 114 119 117 121 100 100 100 100 100 100 100 1 150 
31.  Sivarani 86 77 95 86 82 91 85 100 100 100 100 100 100 100 1 360 
32.  Sridevi 69 74 76 72 70 69 68 100 100 100 100 100 100 100 1 120 
33.  Suganyadevi 86 84 76 73 74 72 74 100 100 100 100 100 100 100 1 60 
34.  Maheswari 76 88 83 84 86 91 91 100 100 100 100 100 100 100 1 30 
35.  Amsavalli 76 89 71 79 75 76 76 100 100 100 100 100 100 100 1 50 
36.  Tamil selvi 90 81 99 90 86 95 89 100 100 100 99 88 100 100 1 60 
37.  Jayalakshmi 84 87 87 75 66 72 69 100 100 100 100 100 100 100 1 1 
38.  Gowsalya 108 94 86 105 84 76 76 100 100 100 100 100 100 100 2 60 
39.  Indrani 82 88 89 93 89 93 86 100 100 100 100 100 100 100 1 90 
40.  Palaniyammal 72 70 82 76 78 88 88 100 100 100 100 100 100 100 1 60 
41.  Rani 92 102 83 70 66 68 64 100 100 100 100 100 100 100 1 60 
42.  Gokul doss 77 106 104 105 102 93 91 98 100 100 100 100 100 100 1 90 
43.  Umameena 71 76 78 74 72 71 70 100 100 100 100 100 100 100 1 420 
44.  Mookammal 73 78 80 76 74 73 72 100 100 100 100 100 100 100 1 420 
45.  Selvi 68 62 60 72 70 74 72 100 99 100 100 100 100 100 1 30 
46.  Muthumari 70 62 60 74 72 74 76 100 100 100 100 100 100 100 2 35 
47.  Balamurugan 74 68 64 74 76 84 90 100 100 100 100 100 100 100 1 35 
48.  Priya 72 80 76 92 84 78 84 100 100 100 99 100 100 100 1 28 
49.  Muthulakshmi 66 60 56 68 72 74 72 100 100 100 100 100 98 100 1 30 
50.  Ravi 76 70 66 72 70 76 74 99 100 100 100 100 100 100 2 35 
51.  Mukila 82 76 74 80 82 86 74 100 100 100 100 100 100 99 1 26 
52.  Murugeshwari 84 80 74 82 80 82 86 100 100 100 100 100 100 100 1 25 
53.  Nandhini 80 74 70 82 80 84 88 100 100 100 100 100 100 100 1 30 
54.  Vimala 78 72 68 78 82 86 84 100 100 100 100 100 100 100 2 35 
55.  Sathyaseelan 72 80 76 82 86 90 98 100 100 100 100 100 100 100 1 35 
56.  Sathya  76 74 70 74 78 82 88 100 100 100 100 100 100 99 1 26 
 
 
 
 
57.  Eswari 80 76 72 78 82 86 84 100 100 100 100 100 100 100 2 28 
58.  Thangadurai 76 72 68 78 82 86 96 100 100 100 100 100 100 100 1 35 
59.  Mahesh 82 80 76 86 90 92 102 100 100 100 100 100 100 100 1 30 
60.  Veeramani 86 84 80 92 96 100 110 100 100 100 100 100 100 100 1 33 
61.  Prabha 80 76 72 82 86 92 96 100 100 100 100 100 100 100 2 28 
62.  Anbuselvan 74 68 64 74 78 82 92 100 100 100 100 100 100 100 1 30 
63.  Karthik 76 72 68 78 82 86 96 100 100 99 100 100 100 100 1 35 
64.  Dhanam 68 72 68 76 80 84 90 100 100 100 100 100 99 100 1 40 
65.  Gomathi 74 70 66 76 82 84 90 100 100 100 100 100 100 100 1 44 
66.  Ranjani 80 76 72 82 86 90 94 100 100 100 100 100 100 100 1 50 
67.  Vasanthakumar 84 80 76 86 88 90 94 98 100 99 100 100 100 100 2 38 
68.  Rajesh kumar 88 84 80 92 96 100 104 100 100 100 100 100 100 100 1 36 
69.  Kannan 76 72 68 78 82 86 90 100 100 100 100 100 100 99 1 40 
70.  Vijaya 82 80 76 86 90 92 96 99 100 100 99 100 100 100 1 46 
71.  Karthiga 86 84 80 92 94 102 104 100 100 100 100 100 100 100 1 50 
72.  Kavitha 74 68 64 74 78 82 86 100 100 100 100 100 99 100 2 40 
73.  Selvam 80 76 72 82 86 90 94 100 100 100 100 100 100 100 1 45 
74.  Kalirajan 68 62 56 68 76 82 86 99 100 100 100 100 100 100 1 38 
75.  Panchavarnam 76 70 66 72 70 76 74 100 98 100 100 100 100 100 1 40 
76.  Nivetha 82 76 74 80 82 86 84 100 100 100 100 100 100 100 2 45 
77.  Ponmeena 84 80 74 82 82 84 88 100 100 100 100 99 100 99 1 60 
78.  Arivuselvi 80 74 70 76 82 80 84 98 100 100 100 100 100 100 1 55 
79.  Balaji 78 72 68 72 80 84 88 100 100 100 100 100 100 100 1 55 
80.  Divya 72 80 76 80 84 86 90 100 100 100 100 100 100 100 1 50 
81.  Raman 76 74 70 74 78 82 86 100 100 100 100 100 100 100 1 42 
82.  Raja 80 76 72 78 82 86 92 100 100 100 99 100 100 100 1 55 
83.  Velmurugan 86 82 76 82 86 90 92 100 100 100 100 100 100 100 1 50 
84.  Sekar 74 70 66 72 76 80 84 99 100 100 100 100 100 100 1 60 
85.  Veeralakshmi 76 72 68 76 80 86 92 100 99 100 100 100 98 100 1 55 
86.  Malathi 74 70 66 72 76 80 86 100 100 100 100 100 100 100 1 40 
 
 
 
 
 
 
 
 
87.  Muthupetchi 80 76 72 82 86 90 96 100 100 99 100 100 100 100 1 45 
88.  Sivakumar 84 80 76 86 88 92 96 100 100 100 100 100 100 100 1 55 
89.  Thamaraiselvi 88 84 80 92 96 102 106 100 100 100 100 100 100 100 1 60 
90.  Muthuselvi 76 72 68 78 82 86 92 100 100 100 100 100 100 100 1 50 
 
 
 
 
ANNEXURE III 
 KEY FOR MASTER SHEET 
No. COLUMNS  
1 
2 
3 
Name of the patient 
IP number 
Age of the patient (in years) 
4 Sex 
        M - male  
        F – female 
5 Weight (in kgs)       
6 Diagnosis 
      F  - Fibroadenoma Breast 
      G  - Gynaecomastia 
      O  - Others   
7 ASA Risk (I & II) 
8 Group 
Group A- Etomidate 0.2 mg/kg + Propofol 0.5 mg/kg (30) 
Group B- Etomidate 0.2 mg/kg + Propofol 1 mg/kg (30) 
Group C- Etomidate 0.2 mg/kg + Propofol 1.5 mg/kg (30) 
9-15 SBP - Systolic Blood Pressure 
16-
22 
DBP - Diastolic Blood Pressure 
23-
29 
MAP – Mean Arterial Pressure 
30-
36 
PR – Pulse Rate 
37-
43 
SP02 
44 No. of Attempts For LMA Insertion 
45 Duration of Apnea (in seconds) 
 
 
 
 
 
 
 
 
ANNEXURE IV 
PROFORMA 
HEMODYNAMIC CHANGES ON LMA INSERTION WITH SAME 
DOSE OF ETOMIDATE AND VARYING DOSES OF PROPOFOL 
Name-                                                     Age/Sex- 
IP. No-                                                     Date- 
Diagnosis- 
Procedure- 
ASA Risk- 
Groups;   A -Etomidate 0.2 mg/kg + Propofol 0.5 mg/kg 
                B -Etomidate 0.2 mg/kg + Propofol 1 mg/kg 
                C -Etomidate 0.2 mg/kg + Propofol 1.5 mg/kg 
A) Time of Induction; 
B) 
Parameters Pre 
Induction 
30sec 60 sec 
(LMA 
Insertion) 
3 
min 
5 
min 
7 min 10 min 
SBP        
DBP        
MAP        
PR        
SPO2        
Etco2        
C) LMA insertion; 
1) No of attempts- 1/2/ >2 
2) Duration of Insertion (In seconds)- 
 
 
 
 
 
 
 
3) Grades of Ventilation; 
  Adequate (Rectangular Capnographic wave with no air leak) 
  Possible (Rectangular Capnographic wave with air leak) 
  Impossible (No Capnographic trace) 
D) Duration of Apnea- 
E) Time of Use of Muscle Relaxant- 
F) Side effects like Pain on injection, Hypotension (>20% reduction), 
Bradycardia (HR<60), Post-operative nausea vomiting and Myoclonus. 
G) Complications in LMA Insertion like Cough, Gag reflex, 
Laryngospasm. 
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